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11General introduction
Multiple myeloma
Multiple myeloma (MM) is a malignant plasma cell disorder that accounts for approximately 10% 
of all hematologic cancers.1-2 MM is characterized by clonal proliferation of malignant plasma 
cells in the bone marrow, which secrete a homogeneous immunoglobulin product known as 
monoclonal (M) protein or paraprotein. Typical features of MM include osteolytic bone lesions, 
renal disease, anemia, hypercalcemia and immunodeficiency.3 
The pathological development of MM is a multistep process and starts with the emergence of 
an asymptomatic premalignant stage of clonal plasma cell proliferation known as “monoclonal 
gammopathy of undetermined significance” (MGUS), occurring in about 3% of individuals 
above the age of 50. MGUS cells secrete monoclonal immunoglobulin (Ig) which may progress 
to smouldering MM and ultimately to symptomatic intramedullary and extramedullary multiple 
myeloma, or plasma cell leukemia; expressing the same Ig. Smouldering MM has a stable in-
tramedullary tumor cell content of >10%, but no osteolytic lesions or other complications of 
malignant MM. Patients with MGUS have a risk to progress to myeloma or a related malignancy 
at a rate of 1% a year.4-5 The prevalence of both MGUS and MM increases markedly with age, 
and is slightly more common in men than in women. The incidence is about two-fold higher 
in African Americans than in Caucasians. The median length of survival after diagnosis is ap-
proximately 3-5 years. 
 
Diagnosis
Diagnostic criteria for MM require the presence of at least 10% plasma cells in bone marrow 
and a monoclonal Ig protein (M-protein; usually > 30 g/L) in the serum or urine. In addition, 
hypercalcemia, renal insufficiency, anemia and lytic bone lesions may be present. 
The clinical presentation of MM varies depending on disease stage. The Durie-Salmon (DS) 
staging system has been the most commonly used staging system for patients with MM since 
1975.6 More recently, the International Myeloma Working Group proposed the International 
Staging System (ISS),7-8 which correlates clinical features with survival. This staging system di-
vides patients into three stages, based on serum β2-microglobulin and albumin levels; Stage 
1: β2-microglobulin concentration < 3.5 µg/mL and albumin concentration ≥ 3.5 g/dL; Stage II: 
β2-microglobulin concentration < 3.5 µg/mL and albumin concentration < 3.5 g/dL, or 3.5-5.5 
µg/mL; or Stage III: β2-microglobulin concentration ≥ 5.5 µg/mL. The ISS was validated and 
demonstrated a median survival of 62 months, 44 months and 29 months for respectively stage 
I, II, and III.
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Molecular genetics of MM
MM is characterized by profound genetic instability, leading to a distinctive combination of gains 
and losses of whole chromosomes, non-random chromosomal translocations and point muta-
tions. Chromosomal translocations are early events in disease progression and seem to play an 
important role in the genetic pathogenesis of MM. 
Based on cytogenetics, multiple myeloma can be subdivided into two groups; hyperdiploid 
and non-hyperdiploid.9 A hyperdiploid karyotype is present in approximately 60% of MM pa-
tients and is characterized by trisomies of odd-numbered chromosomes including 3, 5, 7, 9, 11, 
15, 19 and 21. Patients with hyperdiploid MM tend to have a better prognosis than those with 
non-hyperdiploid disease.10
Many B cell tumors, including multiple myeloma, are characterized by the presence of chro-
mosomal translocations that are mediated by errors in one of the three B cell DNA-modification 
mechanisms. These include immunoglobulin heavy chain (IgH) switch recombination, somatic 
hypermutation and VDJ recombination.11 These translocations results in dysregulation or 
increased expression of an oncogene that is positioned near a strong Ig enhancer. The IgH trans-
locations involve several recurrent chromosomal loci, including 11q13 (cyclin D1), 6p21 (cyclin 
D3), 4p16 (FGFR3 and MMSET), 16q23 (MAF) and 20q11 (MAFB). Primary translocations occur 
early in pathogenesis, whereas secondary translocations are involved in progression of MM. The 
oncogene MYC is involved in secondary translocations. These translocations are not mediated 
by B cell DNA-modification mechanisms, which are not active in healthy or tumor plasma cells. 
In addition, other IgH translocation partners have been identified in approximately 15% of MM 
patients.12-13 
In addition to hyperdiploidy/non-hyperdiploidy and chromosomal translocations; gains and 
losses of specific chromosomal regions occur in all MM patients. The most common abnormality 
observed is a deletion of chromosome 13, which is seen in more than 50% of MM cases and is 
an early event in MM pathogenesis. Such aberrations of chromosome 13 are detectable in all 
stages of myeloma, and normally involve large segments or the entire long arm, however small 
interstitial deletions have also been described.14 Chromosomal gains that recur in more than 
30% of MM patients include 1q, 3q, 9q, 11q and 15q. 
The bone marrow microenvironment
MM is a bone marrow disorder in which malignant monoclonal B cells differentiate into plasma 
cells. The pathogenesis of MM is not exclusively determined by the genetic background of the 
plasma cells. In addition, the interaction of MM plasma cells with the bone marrow microenviron-
ment is also very important. The bone marrow microenvironment consists of the extracellular 
matrix, and five types of bone marrow stromal cells (BMSCs): fibroblastic stromal cells, osteo-
blasts, osteoclasts, vascular endothelial cells and lymphocytes. The proliferation, differentiation, 
and function of MM plasma cells is regulated by reciprocal positive and negative interactions 
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among these cells, which  are mediated by a variety of cytokines, receptors and adhesion mol-
ecules. BMSCs secrete factors including interleukin 6 (IL-6), insulin-like growth factor 1 (IGF1), 
transforming growth factor beta (TGFβ), vascular endothelial growth factor (VEGF), stromal cell-
derived factor 1 alpha (SDF1α), and tumor necrosis factor alpha (TNFα). The interaction of MM 
plasma cells with the extracellular matrix, accessory cells, and secreted cytokines results in the 
activation of signaling pathways that mediate growth, survival, drug resistance, the migration of 
MM cells, as well as osteoclastogenesis and angiogenesis.
Multiple myeloma treatment
In spite of major advances in the treatment of MM, the disease inevitably relapses due to the ac-
quisition of drug resistance. The first standard of care in the 1960s was a melphalan/prednisone 
based regimen as palliative treatment of MM. With this regimen, complete response (CR) rates 
of approximately 5% were achieved. In the early eighties, high-dose melphalan (HDM), followed 
by reinfusion of autologous stem cells was introduced and median survival improved to approxi-
mately 5 years.15 The combination of vincristine, doxorubicin (adriamycin), and dexamethasone 
(VAD) as induction treatment to reduce tumor burden was also widely used, but has now been 
replaced by novel agents.16 Dexamethasone alone appeared to be an alternative, since this regi-
men is probably largely responsible for the effect of VAD.17 In search for the optimal treatment 
for MM, several new agents that target myeloma plasma cells and may overcome resistance from 
conventional agents have been developed including thalidomide,18 bortezomib,19 and lenalido-
mide.20 These compounds have shown promising activity and tolerability in newly diagnosed 
myeloma patients, as well as those with relapsed and/or refractory disease.
Thalidomide
Thalidomide was initially introduced in the late fifties as a sedative-hypnotic drug. Despite its 
withdrawal from the market after its severe teratogenicity was recognized, thalidomide was 
found to be highly effective in a whole range of dermatological, gastro-intestinal and inflamma-
tory diseases, and reappeared in treatment regimens after its potent anti-myeloma effect was 
recognized. The drug is tested on many malignant tumors, including leprosy, Behçet syndrome, 
graft versus host disease and aphthosis in HIV positive patients.
Thalidomide (α-N-phthalimido-glutarimide) is a synthetic derivative of glutamic acid and 
has been used for cancer treatment because of its anti-angiogenic activity. The introduction of 
thalidomide in 1999 has revolutionized clinical management of patients with myeloma. Thalido-
mide treatment has been extensively studied in patients with newly diagnosed, relapsed and/
or refractory MM and has achieved response rates of 30% at relapse and even higher rates at 
presentation.21 
The exact mechanism of action in MM remains to be elucidated, and is still an active area of re-
search. Thalidomide has the ability to inhibit TNFα production by activated human monocytes.22 
14 Chapter 1
Apart from this anti-inflammatory property, thalidomide inhibits levels of other cytokines; IL-1β, 
IL-6,23 VEGF,24 beta fibroblast growth factor (βFGF),25-26 hepatocyte growth factor (HGF),27 and 
granulocyte macrophage-colony stimulating factor (GM-CSF), and in addition upregulates the 
level of intercellular adhesion molecule 1 (ICAM1),28 vascular cell adhesion molecule 1 (VCAM1), 
IL-1029-30 and IL-12.31 
Survival of myeloma plasma cells is dependent on their interactions with the bone marrow 
microenvironment. Disruption of these interactions by thalidomide plays a major role in their 
anti-myeloma activity, which is mediated by the anti-inflammatory, anti-angiogenic,32 and 
immunomodulatory properties of the drug including T cell costimulation and activation of NK 
cells33 and the ability to modulate the production of cytokines and adhesion molecules. 
Thalidomide therapy is however associated with toxic side effects including; constipation, 
peripheral neuropathy, fatigue, rash and especially venous thromboembolism. 
Thalidomide analogues, immunomodulatory drugs (IMiDs), have been synthesized to opti-
mize both anti-TNFα and anti-angiogenic effects, while reducing toxic side effects. Two IMiDs 
that are currently in advanced-phase clinical trials are lenalidomide (CC-5013; Revlimid) and 
pomalidomide (CC-4047; Actimid).
Lenalidomide
Lenalidomide (Revlimid; formerly called CC-5013), is a derivative of thalidomide and belongs to 
the class of immunomodulatory drugs. Despite the similar chemical structures of thalidomide 
and lenalidomide, the toxic profile is different for both novel agents, and lenalidomide is better 
tolerated in patients than thalidomide. Moreover, lenalidomide has shown to be significantly 
more potent in terms of both anti-angiogenic and anti-TNFα activity compared to thalidomide.20 
Lenalidomide has the ability to induce growth arrest or apoptosis in drug-resistant myeloma cell 
lines, abrogate myeloma cell adhesion to bone marrow stromal cells, and modulate cytokines 
that promote the growth, survival, and drug resistance of myeloma cells.34-35
The most common major adverse event associated with lenalidomide is myelosuppression; 
mainly neutropenia and thrombocytopenia, which are manageable by dose reduction and 
growth factor support.20,36 Lenalidomide; in combination with dexamethasone, is associated 
with greater risk of venous thromboembolism and anticoagulant prophylaxis is mandatory. Im-
portantly, common adverse events such as sedation, constipation, and neuropathy are limited. 
Bortezomib
Bortezomib (Velcade; Millennium Pharmaceuticals, Cambridge, MA, formerly known as PS-341) is 
a cobalt containing small molecule which specifically inhibits the 26S proteasome. The ubiquitin-
proteasome pathway is responsible for the degradation of cellular proteins in a controlled fash-
ion. Inhibition of this pathway leads to disruption of the protein regulation involved in cell cycle 
control, cell growth, angiogenesis and apoptosis, which eventually results in cell cycle arrest 
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and apoptosis of myeloma cells.37 As proteasomes are present in all eukaryotic cells, bortezomib 
has potential as a chemotherapeutic agent in many different tumor types; more specifically it 
demonstrates a number of MM specific effects. One central mechanism by which bortezomib 
functions is that it blocks the activation of transcription factor nuclear factor kappa B (NFκB), by 
inhibiting the breakdown of inhibitory kappa B (IκB), subsequently inactivating multiple down-
stream pathways known to be important in MM cell signaling.38 As a result of NFκB inhibition, 
the adhesion of the myeloma plasma cells to BMSCs is decreased, thus increasing sensitivity to 
apoptosis and inhibiting paracrine-mediated growth of MM cells.39 In addition to the inhibition 
of NFκB, MM specific effects include inhibition of angiogenesis, inhibition of DNA repair by cleav-
ing DNA repair enzymes, and impairment of osteoclast activity.40 Bortezomib induced apoptosis 
of MM cells is also associated with caspase 8, 9 and caspase 3 activation.41 
Bortezomib was introduced in MM treatment after demonstrating striking anti-myeloma 
activity in a phase I trial.42 This observation, together with preclinical evidence of anti-myeloma 
activity, provided the rationale for a phase II trial in relapse and/or refractory MM. This led to 
the approval of bortezomib by the FDA in 2003. Bortezomib has also been proven effective in 
the treatment of newly diagnosed MM patients, and has greatly improved the management of 
MM. Clinical trials with bortezomib in relapsed and/or refractory MM have shown high response 
rates and a survival advantage.43-45 Subsequent to this, in newly presenting patients, bortezomib 
combinations have been shown to be associated with excellent complete response (CR) and 
very good partial response (VGPR) rates.46-49 Despite this, patients treated with bortezomib also 
encounter significant toxicity. The most common adverse events are fatigue, weakness, herpes 
zoster reactivation, gastrointestinal disturbances (including nausea, vomiting, diarrhea, and 
constipation), thrombocytopenia, and peripheral neuropathy.44 In addition to MM, bortezomib 
is also used in the treatment of non-hematological malignancies.50 
 
Complications of multiple myeloma treatment with novel agents
Peripheral neuropathy
Peripheral neuropathy (PN) is defined as degeneration of nerves and occurs frequently in plasma 
cell disorders (MGUS, MM, Waldenstroms disease, POEMS syndrome and AL-amyloidosis). 
Although PN can be associated with the underlying disease itself, it can also be related to treat-
ment. PN can involve sensory, motor or autonomic nerve fibers. Assessment of PN is based on 
clinical and elctrophysiological examination, and is usually graded using the Common Toxicity 
Criteria of the National Cancer Institute (NCI-CTC version 3.0). Published research has shown 
the presence of PN in up to 54% of newly diagnosed patients.51-53 Accurate detection of PN is 
however influenced by several factors including; the neurotoxicity grading scale used, patient 
selection, dosing, schedule and duration of treatment, co-medication and co-morbidities. 
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PN is the most frequent and disabling non-hematological side effect from the use of thalido-
mide and bortezomib in MM patients.  Clinical presentation of thalidomide induced PN (TiPN) 
and bortezomib induced PN (BiPN) differs substantially. 
TiPN has an incidence rate ranging from 25% to 75%. TiPN is a predominantly sensory 
axonal neuropathy affecting large and small fibers,54-55 but has also been classified as gangli-
onopathy.55-56 Sensory PN is characterized by symmetric hypesthesia (numbness), paresthesias 
(tingling) or hypesthesia of fingers and toes. Reduction in amplitude or absence of sensory 
nerve action potentials is the most common electrophysiological alteration that can precede 
or worsen symptoms after thalidomide withdrawal, and often does not resolve.57-58 Motor PN 
occurs less frequently than sensory PN, but can still complicate treatment. The nerve damage 
caused by thalidomide is irreversible, and mostly occurs within months. The dosing and duration 
of thalidomide treatment seem to be critical in the development of TiPN. Immediate dose reduc-
tion or withdrawal of thalidomide as soon as signs of TiPN develop is recommended. 
BiPN is typically sensory and characterized by burning pain, distal paresthesias, hyperesthesia, 
and hypoesthesia.59-60 The burning pain is caused by damage to small fibers.61 Electrophysiologi-
cal examination reveals low amplitude of sensory action potentials. In the majority of patients, 
BiPN is reversible and does not seem to be influenced by type or number of previous treatment.62 
BiPN typically occurs after 3 months, reaches a plateau after 5-6 cycles, and does not appear to 
increase.  In relapsed and/or refractory MM, BiPN has been observed in 37%; 22% of which were 
grade 1-2, 13% were grade 3 and 1 % were grade 4.19,43-44 In newly diagnosed MM patients, BiPN 
may affect 47% of patients with up to 16% grade 3-4.46 Motor PN occurs less frequently after 
bortezomib treatment, and often follows sensory PN. 
Although less frequent and less severe, PN has also been observed by lenalidomide, pomalido-
mide and later generation proteasome inhibitors, however such data is limited.63-65 
Risk factors that may predict the occurrence of PN include the presence of PN at baseline, 
alcohol abuse, diabetes mellitus, vitamin deficiencies and viral infections. No effective treatment 
of TiPN and BiPN is currently available and therefore prevention of severe PN by close monitoring 
and dose reduction defines the standard of care.
Venous thromboembolism
Many malignancies, including multiple myeloma, are associated with an increased risk for venous 
thromboembolism (VTE). VTE includes pulmonary embolism (PE) and deep venous thrombosis 
(DVT). One of the major contributing factors to the risk of VTE is treatment with immunomodula-
tory agents; including thalidomide. In addition, disease stage, the type of chemotherapy combi-
nation, and the supportive therapy play a role in the development of VTE following thalidomide 
exposure. Other factors that contribute to VTE risk include mobility and performance status of 
the patient.
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VTE can be associated with MM itself, and there appears to be background rate of 5-10%.66-68 
In patients treated with thalidomide alone, or in combination with other agents such as anthra-
cyclines and dexamethasone,69-70 VTE rates increased to 10-15%.67,71-72 In contrast, is has been 
reported that VTE rates decrease following bortezomib treatment.48,73-76 VTE occurs early after the 
initiation of thalidomide treatment.
The mechanism underlying thalidomide related VTE is not known, however, thalidomide regu-
lates the level of cyclooxygenase 2 (COX2), a well described prothrombotic factor. In addition, 
thalidomide may also influence VTE risk by modulating cytokine levels acting on the endothelial 
cell. This mechanism depends on the differential apoptotic effects of thalidomide in myeloma 
plasma cells compared with endothelial cells, which are protected from apoptosis by a decrease 
in VEGF following thalidomide exposure.77-78 Another biological effect of thalidomide that may 
promote VTE is restoration of endothelial cell protease activated receptor 1 (PAR1) expression 
after damage from doxorubicin, which is often used in combination with thalidomide.79  
Given the risk of thalidomide associated VTE, patients receiving thalidomide treatment 
may benefit from thrombosis prophylaxis. Different strategies have been taken ranging from 
identification of high-risk patients suitable for prophylaxis to prophylactic anticoagulation for 
all patients.80
Pharmacogenetics
The term pharmacogenetics was first introduced in 1959. In pharmacogenetics, the role of a 
patient’s individual genetic variability on the activity, toxicity or kinetics of a particular drug is 
studied. The genetic profile of a patient is an important cause for this interindividual variation in 
drug response. Differences in genetic profiles are often due to inherited single nucleotide poly-
morphisms (SNPs). These SNPs may be located in enzymes involved in drug metabolism, such as 
the cytochrome P450 enzymes and ATP-binding cassette (ABC) transporters, and genes coding 
for drug targets. However, not only drug metabolizing enzymes play a role in drug response, 
genes involved in mechanisms as inflammation, immunity, DNA repair and apoptosis may 
contribute to drug response. The interindividual differences may be caused by a difference in 
concentrations of the intended compound at the intended site of action, the pharmacodynamics 
of a drug. On the other hand, interindividual differences in drug response can be due to dif-
ferential pharmacokinetics, which includes absorption, distribution, metabolism, and excretion 
of the drug. Pharmacogenetics will allow adapting a treatment to the genetic profile of a patient.
Genetic variation
Polymorphism (from Greek: poly “many”, morph “form”) refers to a variation in the DNA sequence 
among individuals. Polymorphisms which have a population frequency of 1% or more are con-
sidered to be common polymorphisms. Genetic polymorphism ranges from single nucleotide 
changes in the DNA (SNPs), small insertions and deletions of a number of nucleotides, through 
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insertions, deletions, and duplications of large segments of DNA, to translocation of chromo-
somal segments and even changes in chromosomal number. Although rare genetic variants 
exist, most of the variation in the human population is attributable to common variants (alleles); 
SNPs.
Single nucleotide polymorphisms
A SNP is defined as a common DNA sequence variation occurring when a single nucleotide (A, 
T, C, or G) in the genome differs between individuals (or between paired chromosomes in an 
individual). SNPs arise due to mutation, normally due to a misincorporation of a nucleotide dur-
ing replication, or by chemical or physical mutagenesis. Throughout the genome, SNPs occur 
every 1000-3000 base pairs and have been identified in 93% of all known genes.81
Almost all common SNPs have only two variants (alleles). The major allele is the allele found 
at highest frequency, and the lower frequency allele is referred to as the minor allele. The minor 
allele frequency (MAF) refers to the frequency at which the less common allele of the SNP occurs 
in a particular population. The MAF varies with ethnicity and gender due to demographic influ-
ences undergone by the population such as migration, genetic drift, and population specific 
selection. Disease status also affects variability in the frequency of SNPs. It is estimated that there 
are around 11 million common, > 1% MAF SNPs in the human genome and ~7 million with MAF 
> 5%.82
SNPs can be present in coding, non-coding or intergenic regions. If located in a coding 
sequence, they can change amino acid sequence (nonsynonymous SNPs; Figure 1A) with cor-
respondent change to protein function to be missense (replacing one amino acid with another), 
or nonsense (producing an aberrant stop codon). When the amino acid sequence is not changed 
by a SNP, it is a synonymous or silent variant (Figure 1B). Both nonsynonymous and synonymous 
SNPs may cause a change in protein structure and function, the level of protein expression, or 
might influence the assembly of the final messenger RNA template from which the protein is 
synthesized (alternative splicing). They can also influence promoter activity or the ability of a 
protein to bind its substrate. Therefore, SNPs may contribute to altered pharmacodynamics and 
pharmacokinetics, consequently altering the response to therapy and development of adverse 
reactions. Identification of SNPs that are linked to or contribute to individual drug response vari-
ability, may therefore allow the design of personalized regimens based upon genotype.
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DNA
mRNA
protein
A CG G A G G C C
A CG G A G G C C
C T C T G C C G G
Glu  Thr  Ala
Synonymous SNP
A CG G A A G C C
A CG G A A G C C
C T C T G T C G G
Glu  Thr  Ala
DNA
mRNA
protein
Nonsynonymous SNP
A CG G A G G C C
A CG G A G G C C
C T C T G C C G G
Glu  Thr  Ala
A AG G A G G C C
A AG G A G G C C
C T C T T C C G G
Glu  Lys  Ala
A
B
Figure 1. Schematic overview of SNP types. (A) A change of a single nucleotide leads to an amino acid 
change. The C and A nucleotide are transcribed to mRNA. In the protein, ACG is translated into a Threonine 
amino acid whereas AAG is translated into a Lysine amino acid. (B) A change of a single nucleotide does 
not lead to an amino acid change. The G and A nucleotide are transcribed to mRNA. ACG and ACA are both 
translated into a Threonine amino acid. 
Strategies for SNP analysis
To study the association between genetic variation and treatment related toxicity or treat-
ment outcome, different approaches can be used including a candidate gene approach and a 
genome-wide approach. 
The most common approach employed to study associations between a genetic variant and 
a disease has been to examine one or more candidate genes based on a hypothesis-driven 
strategy. This strategy requires knowledge of the biological basis of the disease or trait, along 
with some knowledge of the function of the gene or genes involved.
The genome-wide approach is free of any hypothesis regarding which genes are involved. 
With the improvement of genotyping technologies and the exponentially growing number of 
SNPs, genome-wide association analyses have become a useful tool. A genome-wide associa-
tion analysis makes use of the knowledge that the human genome has a haplotype structure.83 
Haplotypes are particular combinations of SNPs observed together on a chromosome that are 
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inherited together as a unit. These SNPs segregate together more often than expected, and are 
said to be in linkage disequilibrium (LD). LD is dependent on allele frequencies, as well as recom-
bination. It is therefore only necessary to genotype a small number of SNPs from a particular 
haplotype, which should provide the information about the other SNPs within this haplotype. In 
addition, ‘tag SNPs’ are SNPs in high LD that represent a certain region of the genome, and are 
therefore useful in genome-wide SNP association studies. Still, several hundred thousand SNPs 
are analyzed in this approach to gather genome-wide SNP information. One of the advantages 
of the genome-wide approach is that it enables the detection of the contributions of novel or 
less obvious genes. 
Bank On A Cure SNP panel
The Bank On A Cure (BOAC) SNP panel was designed to examine the association of genetic 
variations with disease risk and outcome in multiple myeloma.84 DNA from multiple cooperative 
groups was banked and genotyped using this custom SNP panel. The panel comprises 3404 
SNPs in 964 genes, selected using a candidate gene approach. Pertinent candidate genes were 
selected by myeloma experts in the International Myeloma Foundation consortium. An initial list 
was supplemented with referencing established pathway databases,85-87 generating a candidate 
gene list spanning 67 molecular pathways important in the biology of myeloma, treatment re-
sponse, and side effects to conventional and novel agents (Table 1). A literature search88 was con-
ducted to identify SNPs that had been previously reported as having a functional consequence 
or relevance in prior etiologic or treatment outcome studies. The following criteria were used 
to select SNPs; having a MAF greater than 2%, from the candidate gene list, nonsynonymous 
SNPs present in dbSNP/SNP 500,89 promoter variants present in homologous regions between 
human and mouse, in or adjacent to a transcription binding site using the Promolign database,90 
and promoter SNPs identified in the Functional Element SNPs Database (FESD).91 Tag SNPs in 
genes considered to be of particular relevance along with population discriminating admixture 
variants form the X chromosome.92 Finally, all nonsynonymous SNPs with a MAF greater than 
2% in phosphatase, kinase and transferase genes present in the dbSNP database were included.
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Table 1. Functional categories on the BOAC custom-built SNP panel.
Functional category No. of genes No. of SNPs
ADME/DMET 130 445
Cancer 406 1558
Carbohydrate Metabolism 69 384
Cell Cycle 230 867
Cell Death 433 1662
Cell Signaling 90 352
Cell-To-Cell Signaling and Interaction 248 880
Cellular Growth and Proliferation 420 1451
Cellular Movement 227 923
DNA Replication, Recombination, and Repair 204 854
Drug Metabolism 20 114
Gene Expression 240 951
Hematological Disease 223 876
Immune Response 247 985
Lipid Metabolism 146 664
Molecular Transport 170 708
Nucleic Acid Metabolism 30 161
Skeletal and Muscular Disorders 64 289
Skeletal and Muscular System Development and Function 77 278
Signaling Kinase, Phosphatase, Transferase 198 885
Inflammation & Immunity 196 813 
Table adapted from Van Ness et al.84
The 3404 pre-selected SNPs can be simultaneously identified using the Affymetrix Targeted 
Genotyping System, which is based on a molecular inversion probe technology (Figure 2).93-94
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4 Probe release
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P2 Tag X2
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H2 H1 P1
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C G A TG G A G G C C C A
G C C T C T C C G G G T
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Probe
Probe
Genomic
C G A TG G A G G C C C A
G C C T C T A C C G G G T
Genomic
Probe
Probe
Genomic
C G A TG G A G G C C C A
G C C T C T A C C G G G T
Genomic
Probe
Probe
Genomic
Genomic
Probe
Figure 2. Molecular inversion probe technology. The top panel shows an unreacted probe (top) and an 
inverted probe (bottom). The probe consists of; 2 homology regions (H1 and H2) unique to each probe, 2 
common PCR primer regions (P1 and P2), 1 bar code (Tag) unique for each locus, and 2 common cleavage 
sites (X1 and X2). The bottom panel shows the enzymatic probe inversion. (1) Genomic DNA, probes, ligase, 
and polymerase is heat-denatured. Homology regions H1 and H2 hybridize to complementary sites on the 
genomic DNA. A circular structure with a single nucleotide gap is created. (2) In four separate reactions, unla-
beled dATP, dCTP, dGTP or dTTP are added respectively. DNA polymerase adds the nucleotide to the single 
nucleotide gap when the nucleotide is complementary. (3) DNA ligase closes the gap and a covalently closed 
circular molecule is formed (left) and exonucleases digest the non-complementary nucleotides and excess 
linear probes (right). (4) Probes are released from the genomic DNA and cleaved at the abasic site. (5) PCR 
amplification of probes that were circularized in the gap fill reaction. 
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MicroRNAs
MicroRNAs (miRNAs) are a class of small non-coding single stranded RNAs of approximately 22 
nucleotides in length that are found in both plants and animals.95 So far, more than 500 human 
miRNAs have been reported in literature.96
MiRNA biogenesis (Figure 3) starts in the nucleus where miRNAs are initially transcribed 
by RNA Polymerase II (Pol II) to form long primary transcripts known as primary-miRNAs (pri-
miRNAs), which are capped and polyadenylated. The pri-miRNAs are processed in the nucleus by 
the microprocessor complex and associated factors; including the RNase II enzyme Drosha and 
its co-factor, Pasha (also known as DGCR8) to form a stem-loop hairpin structure, a pre-miRNA of 
50-70 nucleotides, in which the miRNA itself is contained.97-100 The pre-miRNAs are exported into 
the cytoplasm by the RanGTP-dependent transporter exportin 5.101-103 Another RNAse III enzyme, 
Dicer, processes them further into a double stranded RNA of approximately 22 nucleotides in 
length that contains the mature miRNA and an oligonucleotide of the other arm of the hairpin; 
referred to as miRNA:miRNA* duplex.104-107 The functional element of the duplex is determined 
when it is incorporated into the multiprotein RNA-induced silencing complex (miRISC) complex. 
Only one strand remains stably associated with miRISC, which becomes the mature miRNA. 
MiRNAs primarily function as translational repressors by binding to mRNA in the 3’UTR (un-
translated region) with a certain degree of complementation. The mature miRNA incorporated 
in the miRISC functions as guide, directing the complex to the 3’UTR of their target genes. The 
degree of complementation can be either perfect or imperfect, resulting in mRNA degradation 
or protein translation inhibition, respectively (Figure 3). The inhibition mechanism depends on 
several factors including the miRNA sequence, the target mRNA sequence and the exact compo-
sition of the miRISC complex.108-109
Because miRNAs are capable of binding their targets with imperfect complementation, each 
miRNA can possibly interact with a large number of genes; conversely, a single gene can harbor 
multiple miRNA recognition sites. This fact puts a challenge on the identification of miRNA tar-
gets and several algorithms have been developed to predict miRNA targets.110-112 Critical in the 
prediction of targets is the ‘seed sequence’ of the miRNA, which consists of 6–7 nucleotides of 
the 22 nucleotides comprising a miRNA.113 However, experimental verification is required before 
a gene can be considered as a genuine miRNA target.
MiRNAs are involved in critical biological processes including cellular growth and differen-
tiation, development, and apoptosis.95 Furthermore, miRNAs have been implicated in cancer, 
which is highlighted by the observation that about 50% of annotated human miRNAs is located 
at fragile sites across the human genome. These fragile sites are often deleted or amplified at a 
common breakpoint, and frequently associated with cancer.114 This observation indicated that 
miRNAs might play a crucial role in cancer progression. 
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Large-scale miRNA expression profiling has been explored in many cancer types including 
hematological malignancies such as chronic lymphocytic leukemia115 and acute myeloid leuke-
mia.116-117 However, little is known about the miRNA expression in MM.118-123
Drosha
miRNA Gene
Pri-miRNA
Pre-miRNA
Nucleus
Cytoplasm
Dicer
RNA Pol II 
Exportin
RanGTP
miRNA:miRNA* 
duplex
Mature miRNA
miRISC
complex
mRNA
5’UTR 3’UTR
Translational repression
5’UTR 3’UTR
mRNA degradation
Figure 3. Schematic representation of miRNA biogenesis.
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Aims and outline of the thesis
Pharmacogenetics is the study of how genetic variants affect drug response. This genetic varia-
tion, often due to SNPs, can affect a patient’s response to drugs and the development of toxic 
side effects. Therefore, gaining better insight into the SNP profile of patients will eventually allow 
individualized treatment and prediction of side effects.
The thesis presents work divided into two parts. The first part (Chapters 2 through 6) focuses 
on SNP associations with adverse events of treatment and treatment outcome in MM patients. 
In Chapter 2, the association between inherited genetic variation and the development of 
MM is discussed. The introduction of novel agents, such as bortezomib and thalidomide, has 
revolutionized clinical management of patients with MM. However, the therapeutic use of these 
novel agents is accompanied by various side effects and 30% of the patients have to stop treat-
ment prematurely. SNPs located in the genes involved in detoxification of drugs can lead to 
alterations in drug-metabolizing enzymes, resulting in altered pharmacokinetics of therapeutic 
agents, thereby influencing a patient’s response to treatment and treatment related toxicity. 
Thalidomide treatment is associated with the development of VTE. Genetic associations with 
VTE in MM patients treated with thalidomide are discussed in Chapter 3. In Chapters 4, 5, and 6 
we have focused on MM treatment with novel agents; bortezomib and thalidomide, which are 
accompanied by PN. In these chapters the question of whether SNPs can be used to identify 
patients at risk for PN, and whether SNP association analyses can provide insights in the mecha-
nisms underlying treatment induced PN is explored. Specifically, in Chapters 4 and 5, genetic 
associations with TiPN and BiPN are discussed respectively. Chapter 6, discusses the differences 
between vincristine induced PN (ViPN) and BiPN during induction treatment in MM patients. 
The second part of this thesis (Chapters 7 and 8) deals with miRNA expression in MM patients. 
MiRNA expression profiling is presented in Chapter 7 as a means to gain more insight in miRNA 
expression patterns in MM. In Chapter 8, we discuss miRNA-15a and miRNA-16 expression in 
relation to chromosome 13 deletion; a recurrent chromosomal abnormality in MM. 
Finally, the results as described in this thesis and their future perspectives are discussed in 
Chapter 9.
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Chapter 3
Abstract
A venous thromboembolism (VTE) with the subsequent risk of pulmonary embolism is a major 
concern in the treatment of multiple myeloma patients with thalidomide. The susceptibility to 
developing a VTE in response to thalidomide therapy is likely to be influenced by both genetic 
and environmental factors. To test genetic variation associated with treatment related VTE in pa-
tient peripheral blood DNA, we used a custom-built molecular inversion probe (MIP) based single 
nucleotide polymorphism (SNP) chip containing 3404 SNPs. SNPs on the chip were selected in 
“functional regions” within 964 genes spanning 67 molecular pathways thought to be involved 
in the pathogenesis, treatment response and side effects associated with myeloma therapy. 
Cases and controls were taken from three large clinical trials; MRC Myeloma IX, HOVON-50 and 
ECOG EA100, which compared conventional treatments with thalidomide in myeloma patients. 
Our analysis showed that the set of SNPs associated with thalidomide related VTE were enriched 
in genes and pathways important in drug transport/metabolism, DNA repair and cytokine bal-
ance. The effects of the SNPs associated with thalidomide related VTE may be functional at the 
level of the tumor cell, the tumor related microenvironment, and the endothelium. The clinical 
trials described in this paper have been registered as follows: MRC Myeloma IX: ISRCTN68454111, 
HOVON-50: www.clinicaltrials.gov under identifier NCT00028886, and ECOG EA100: www.clini-
caltrials.gov under identifier NCT00033332.
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Introduction
The introduction of thalidomide and other immunomodulatory drugs has revolutionized clinical 
management of patients with myeloma. Thalidomide treatment has achieved  response rates 
of 30% at relapse and even higher rates at presentation.1 Investigation of the specific effects 
of thalidomide in myeloma remains an active area of research where up regulation of ICAM-1,2 
VCAM-1, IL-10,3-4 IL-12,5 and decreased levels of VEGF,6 bFGF,7-9 HGF,10 TNFa,11 IL-6,12 sIL-6-R,13 are 
thought to play a role in the mechanism of action, which suggests that thalidomide effects the 
myeloma cell directly as well as its microenvironment.14
The therapeutic use of thalidomide has focused attention on venous thrombotic events 
(VTEs). There appears to be a background rate of 5-10% VTE15-16 in myeloma possibly due to 
enhanced expression of tissue factor and VEGF,17 acquired cytokine mediated activated protein 
C resistance18 and downregulation of thrombospondin.19 In intensively treated patients exposed 
to thalidomide the rate of VTE increases to 10-15%,16,20-21 the mechanisms leading to this are 
uncertain, but it is known that thalidomide regulates the level of COX-2,22-25 a well described 
prothrombotic factor. Thalidomide may also modulate the VTE risk by its effects on cytokine 
levels acting on the endothelial cell, a mechanism dependent on the differential apoptotic ef-
fects of thalidomide in myeloma plasma cells compared to endothelial cells, which are protected 
from apoptosis by decrease of VEGF by thalidomide,26-28 In this context, it is known that stressed 
human umbilical vein endothelial cells (HUVECs) upregulate a number of procoagulant factors 
including PAR-1, P-selectin, E-selectin and tissue factor, with thalidomide protecting these cells 
from apoptosis potentially enhancing these procoagulant effects, there is some clinical evidence 
for this mechanism in non-myeloma settings.29-33
The risk of developing a VTE following thalidomide exposure depends upon a number of fac-
tors including, disease stage, the type of chemotherapy combination and the supportive therapy 
used. Patient-specific variables also contribute to the excess risk of VTE including immobility, 
poor performance status, and dehydration. An important clinical observation is that VTEs occur 
early after the initiation of thalidomide treatment and VTE rates are increased in patients when 
used in conjunction with anthracycline and dexamethasone34,35 and can decrease  following 
exposure to bortezomib.36-40
The excess risk of thalidomide associated VTE in myeloma has been managed by a number of 
different strategies, ranging from the identification of high risk patients suitable for prophylaxis 
to prophylactic anticoagulation for all patients.41 Aspirin has been suggested to be effective,42 
but its use is controversial because of the lack of a readily applicable mechanism justifying its 
use. In this work we have examined inherited genetic variation associated with VTE following 
thalidomide exposure in myeloma patients, using a custom array-based SNP detection tool, in an 
effort to elucidate the molecular mechanisms contributing to increased risk.
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Materials and methods 
Clinical samples
Peripheral blood DNA samples were obtained from 544 myeloma cases derived from three 
randomized clinical trials comparing standard induction treatment for presenting patients with 
thalidomide containing regimens derived from the Medical Research Council (MRC) Myeloma 
IX (1966 patients) the Eastern Cooperative Oncology Group (ECOG) EA100 (900) patients and 
the HOVON-50 study (400 patients; Figure 1). The dose of thalidomide (100-200 mg daily) was 
comparable between the 3 studies, but the chemotherapy combination used differed. The 
samples were used as the basis for 2 nested case-control comparisons examining the inherited 
genetic contribution to the risk of VTE as a consequence of thalidomide exposure. In a discovery 
set analysis, we compared the genotype results derived from 157 Myeloma IX patients with VTEs, 
of which 104 were related to thalidomide exposure and 53 unrelated, to a control group of 315 
age- and sex-matched myeloma patients also in the trial who did not develop a VTE (198 thalido-
mide exposed patients and 117 non thalidomide exposed). To validate the frequency distribu-
tions, we carried out a second case-control comparison using 23 patients with VTE treated with 
thalidomide and 49 thalidomide treated controls. To ensure homogeneity of allelic frequencies 
only patients of European descent were included. This study has been approved by The United 
Kingdom Multicentre Ethics Committee. 
Clinical trials
The Myeloma IX study comprises 2 randomizations: an intensive pathway for younger, fitter 
patients comparing CVAD (cyclophosphamide 500 mg orally weekly, vincristine 0.4 mg intra-
venously on days [d] 1-4), doxorubicin 9.0 mg/m2 on d1-d4, dexamethasone 40 mg on d1-d4 
and d12-d15), delivered by a central venous access device with oral CTD (cyclophosphamide, 
thalidomide, dexamethasone) using the same doses of cyclophosphamide and dexamethasone 
combined with 200 mg of thalidomide. The second randomization, for older, less-fit patients, 
compared an attenuated dose of CTD (thalidomide 100-200 mg) to melphalan (7.0 mg/m2 orally 
on d1-d4 every 28 days) and prednisolone (MP). All patients at high risk of VTE, defined by clinical 
criteria, were identified; prophylactic anticoagulation was considered by the treating physician, 
but it was not specified. The ECOG EA100 study randomized patients to either dexamethasone 
alone 40 mg daily from d1 to d4 and d12 to d15 or the same dose in combination with thalido-
mide 200 mg daily. In the study set, from which samples were available, no thromboprophylaxis 
was used on either arm. The HOVON-50 study randomized patients to either 3 cycles of VAD 
(vincristine 0.4 mg, intravenous rapid infusion on d1-d4; doxorubicin 9 mg/m2, intravenous rapid 
infusion on d1-d4; and dexamethasone 40 mg orally, d1-d4, d9-d12, and d17-d20) or the same 
regimen but with thalidomide replacing the vincristine (TAD). Thalidomide was given daily at a 
dose of 200 mg, but could be escalated to 400 mg. All patients in the TAD arm received throm-
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boprophylaxis with low-molecularweight heparin (LMWH). Incident cases of VTE were defined 
using clinical criteria, and no screening approach was used. The identification of VTE represents 
current clinical practice with initial clinical identification and subsequent confirmation and 
definition of the extent of thrombosis using a definitive radiologic investigation. Central venous 
thrombosis and line-related thrombosis were defined by clinical criteria and subsequently con-
firmed by ultrasound.
Genotyping, SNP selection, and chip design
DNA was extracted from frozen white blood cell pellets using the Qiagen Flexigene kit (Valencia, 
CA) and quantified using a Nanodrop spectrophotometer (Wilmington, DE). Genotyping was 
performed using the Affymetrix targeted genotyping platform (Santa Clara, CA), which is based 
on a molecular inversion probe technology.43-45 Patient samples were assayed using a custom-
built 3.0K panel comprising 3400 SNPs. SNPs were selected using a hypothesis-driven strategy. 
Pertinent candidate genes were nominated by myeloma groups in the International Myeloma 
Foundation - led “Bank On A Cure” (BOAC) consortium. An initial list was supplemented with 
referencing pathway databases, including BioCarta, Kyoto Encyclopedia of Genes and Genomes 
(KEGG),46-47 and Pathway Assist (Ariadne Genomics, Rockville, MD),48 generating a candidate 
gene list spanning some 67 molecular pathways important in the biology of myeloma, treat-
ment response, and side effects to conventional and novel agents, which included important 
genes within the clotting and prothrombotic pathways. Taking the BOAC candidate genes, we 
completed a literature search49 to identify SNPs that had been previously reported as having a 
functional consequence or relevance in prior etiologic or treatment outcome studies. SNPs with 
a minor allele frequency (MAF) greater than 2% were then systematically selected from the can-
didate gene list using the following criteria: nonsynonymous SNPs present in dbSNP/SNP 500;50 
promoter variants present in homologous regions between human and mouse, in or adjacent to 
a transcription binding site utilizing the Promolign database;51 and promoter SNPs identified in 
the Functional Element SNPs Database (FESD).52 We then included Tag SNPs in genes considered 
to be of particular relevance along with population discriminating admixture variants from the 
X chromosome.53 Finally, we included all nonsynonymous SNPs present in the dbSNP database 
in phosphatase, kinase, and transferase genes with a MAF greater than 2%. The genes and SNPs 
comprising this panel with allele frequencies are available online.54
Statistical analyses
We carried out a Fisher exact Hardy-Weinberg equilibrium (HWE) test at a P value less than or 
equal to 0.001 on all SNPs across the control samples and removed SNPs departing from HWE 
from the analysis to filter erroneously performing SNPs. We then carried out a “test of missing-
ness” on patient and control status to control for any bias in missing data. We performed a basic 
Fisher (allelic) association test for disease trait based on a comparison of patients with controls. 
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We then completed the analysis using 3 genetic models: additive (Cochran-Armitage trend 
test), dominant, and recessive. To account for multiple testing, we carried out label swapping 
permutation procedures on each of the SNP assays, with their most significant models used to 
calculate an empirical P value for each SNP. The size of the dataset generated on the BOAC panel 
is much larger than a typical candidate gene study; we therefore carried out this analysis in the 
program PLINK,55 an open-source whole genome association analysis toolset designed for large 
dataset analysis. The test for epistasis involved testing all pairwise combinations of SNPs. The 
output consists only of pairwise epistatic results above a P level less than 0.001 for each SNP. 
Combinations were restricted to SNPs more than 1 MB apart or on different chromosomes. This 
test is only an approximation of the extent of epistasis (SNP-SNP interaction), as it is a naive 
statistic that does not take linkage disequilibrium (LD) into account. We characterized the haplo-
types using Haploview 4.0,56 and completed haplotype trend regression in Helix-tree (Bozeman, 
MT). Meta-analysis was performed in SPSS 14.0 (Chicago, IL) using a meta-analysis macro written 
by Garcia-Granero.57 Combined odds ratios were calculated using Mantel-Haenszel method for 
fixed events. 
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Figure 1. Simplified treatment arms of ECOG EA100, HOVON-50, and Myeloma IX studies.
Biological relevance of the associated SNPs
To examine the possible functionality of the thalidomide related VTE associated SNPs, we used 2 
complementary in silico algorithms for prediction of the putative impact of missense variants on 
protein function, PolyPhen58 (structural) and the SIFT59 (conservation), shown in Table S8. We 
then used a bioinformatics approach to define the pathways potentially deregulated by the as-
sociated and validated genes. We used the functional annotation tool on the DAVID Bioinformat-
ics Resources/Database,60 to characterize which pathways are most represented in associated 
gene groups from our single-point analysis. The gene coverage of the BOAC chip was used to 
form a template/background set, against which associated genes and validated associated SNPs 
with VTE were tested (Table S9).
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Recursive partitioning
To develop a predictive model for the identification of patients at high risk of VTE, we first divided 
the combined dataset into a training and validation set. We then applied the method of recursive 
partitioning to the training set.61 In this approach, a regression tree is built by first finding the 
SNP which best splits the data into 2 groups (VTE, no VTE). This process is repeated over and over 
again for the individual subsets until the subgroups reach a minimum size or no improvement 
can be made. The second stage in recursive partitioning consists of cross validation by trimming 
back (pruning) the typically complex full tree. The best pruned trees are examined to find which 
one has the largest classification rate while using the smallest number of SNPs. Sensitivity and 
specificity are determined for the training and validation set. A receiver operator characteristic 
(ROC) curve is used to determine the best sensitivity and specificity trade-off.
 
Results
Clinical results 
The Myeloma IX analysis is based on 1966 randomized patients: 984 patients treated with CTD, 
557 patients treated with CVAD, and 425 patients treated with MP. In the intensive pathway, the 
overall rate of VTE was identical in both arms (Table S1). However, there was a qualitative dif-
ference between the 2 arms, with deep vein thrombosis (DVT) predominant in the thalidomide 
treated group and line related thrombosis predominant in the CVAD group. In the nonintensive 
pathway, very few VTEs were seen in the MP group, whereas in the CTD group there was a 
15.0% VTE rate. The median time to VTE in each of the groups was approximately 12 weeks from 
treatment initiation. The HOVON-50 study had VTE rates of 12.1% and 11.8% in the thalidomide 
related and standard arms, respectively, with median time to first event of 8.9 weeks. In the 
ECOGEA100 study, the VTE rates were 17.0% and 3.0% in the thalidomide related and standard 
arms, respectively.62
Panel, sample, and SNP assay validation
Affymetrix constructed and validated the SNP panel reagents. A total of 59 DNA samples from 
the extensively characterized and genotyped Coriell CEPH HapMap series were assayed to vali-
date the call performance of the BOAC panel. A total of 58 Coriell CEPH HapMap samples were 
also used in a correlation analysis between the BOAC chip and HapMap study. We did not obtain 
HapMap data for the remaining Coriell samples and did not perform a correlation analysis. A 
total of 2606 SNPs were present on both the chip and HapMap. There was a SNP call correlation 
of 96.1% at 95% confidence levels; SNPs falling below this were removed from the analysis (132 
SNPs). The Coriell sample genotype validation was replicated in BOAC labs to ensure there was 
no differential bias in genotyping scoring between sites. Patients and controls were also geno-
typed together throughout the experiment to avoid any differential bias in genotype scoring. 
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We observed complete agreement between the known sex and inferred SNP-based sex in all 
samples. We used Eigenstrat63 to highlight population stratification and removed 4 population 
outliers from the analysis. A number of admixture SNPs were included in the SNP panel.53 Geno-
type calls for these SNPs demonstrated that patients and controls reflected a sample set drawn 
from a European population.
Genotyping results and validation 
The MRC Myeloma IX study is the largest of the datasets in this study; to capitalize on this, we 
chose to focus our discovery set on this study and to validate the results on combined data sets 
from HOVON-50 and ECOG EA100 trials. A set of SNPs for validation was defined by separately 
determining the distribution of the most significant SNPs in the MRC myeloma IX, HOVON-50, 
and ECOG EA100 studies. Following testing allelic distributions using the Fisher test to an em-
pirical P value less than 0.05 in the discovery set, 120 SNPs were found to be associated with 
thalidomide associated VTE, involving 71 genes (Table S2). Further genetic model association 
analysis in Myeloma IX data are listed in Table S3; allelic and genetic model association for 
non–thalidomide related VTEs are listed in Tables S4 and S5, with allelic and genetic model 
association for HOVON-50/EA100 trials shown in Tables S6 and S7. With the aim of identifying 
genes modulating the risk of thalidomide related thrombosis, we compared the distribution of 
the SNPs identified in this analysis between 3 subgroups: thalidomide associated VTEs from MRC 
Myeloma IX, non–thalidomide associated VTEs from MRC Myeloma IX, and thalidomide associ-
ated VTEs from the combined HOVON-50/ECOG EA100 studies. A Venn diagram depicting the 
overlapping associated genes in the 3 analyses is shown in Figure 2.
Validation of thalidomide related VTE associated SNPs
To validate the genotyping results in the discovery set, we discarded SNPs with conflicting fre-
quency distributions between studies. This approach may have led to the removal of a number 
of true positives from the analysis because of the small sizes of the HOVON-50 and ECOG EA100 
datasets. SNPs with small effect sizes were also removed from the analysis. As a result of this 
process we found 24 SNPs (Table 1) associated with VTE in the “discovery set” with consistent 
distributions in the 2 validation datasets. Haplotype analysis showed that 6 SNPs were in linkage 
with a stronger proxy SNP and as such were discarded, leaving 18 validated SNPs associated with 
thalidomide related VTEs. A “forest plot” with odds ratios (ORs) and confidence intervals (CIs) for 
the combined and individual datasets of the validated SNPs was generated (Figure 3).
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Gene-gene interactions
To examine gene-gene interactions, we looked for pairwise combinations mediating risk. The 
epistatic interactions with a P value less than 0.001 are shown in Table S10.
Recursive partioning analysis 
To maximize the size of the dataset and thus to maximize the ability to identify relevant SNPs, 
we combined all the datasets into one and randomly split it into a two-thirds training set and 
one-third validation set. The data were stratified by trial and VTE patients to ensure that the 
training and validation sets were comparable. These data included 165 subjects without VTE and 
84 subjects with VTE in the training set and 82 subjects without VTE and 42 subjects with VTE 
in the validation set. The training set was used to identify the top associated genes and SNPs by 
association at the level of P less than 0.05 listed in Table S2. These SNPs were used in a recursive 
partitioning analysis carried out on the test set with the aim of finding the combination with the 
best sensitivity and specificity for the identification of VTE. We pruned the tree to find the tree 
with the highest classification and smallest number of SNPs. The results of this analysis (Figure 
4) showed that using 7 SNPs (rs7011 in CINP, rs289747 in CETP, rs610529 in ALDH1A1, rs3829963 
in CDKN1A, rs2608555 in GAN, rs699947 in VEGF, and rs168351 in ALDH1A) it was possible to 
identify VTEs correctly in 70% of individuals with a specificity of 59% and sensitivity of 81%. This 
set of SNPs performed well in the validation set; the set was able to correctly classify VTEs in 61% 
of individuals with a specificity of 30% and sensitivity of 77% (Tables S12 and S13).
 
Discussion
This study has analyzed data from 3 large randomized clinical studies comprising 3100 patients, 
comparing induction treatment for newly presenting patients with myeloma with and without 
thalidomide. The results of this analysis show that the background rate of VTE in MP treated 
patients is very low and significantly increases with the addition of thalidomide. In addition we 
provide further evidence that infusional regimes based on VAD increase VTE rates to around 
15%, which is similar to the rates seen with oral thalidomide combinations. The nature of the 
thrombotic events is qualitatively different between regimes; with all events being either DVT or 
pulmonary embolism (PE) in the oral thalidomide treated patients, whereas in the intravenous 
treatment, 50% of the events are central line related. There is a doubling of non-central line 
related VTE rates in the thalidomide treated patients compared with those receiving infusional 
induction regimens. The median time to VTE in each of the treatments is approximately 50 to 
60 days after the initiation of treatment, a time reflecting the rapid dissolution of the myeloma 
clone. We have shown previously that response rate is enhanced in thalidomide containing 
regimes compared with VAD-like regimes, and we postulate that this is important in determining
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Figure 3. Forest plots showing distribution of validated SNPs associated with thalidomide related VTEs across 
the Myeloma IX, HOVON-50, and ECOG EA100 trials. Error bars indicate upper and lower 95% CIs.
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the VTE risk.64 The mechanistic importance of increased response rates with VTE risk may explain 
the reduced numbers of VTEs seen in relapsed patients, who are frequently drug resistant and 
show lower response rates. It is also important not to discount increased VTE risk due to changes 
in the disease biology related procoagulant profiles of such relapsed patients.
Using a nested case-control design with readily defined exposure and clinical endpoint, this 
study has given useful information about inherited genetic variants with a moderate effect size 
affecting the thrombotic response to thalidomide exposure. We chose to use the MRC Myeloma 
IX study as our initial discovery set because it was the largest and had the most data available with 
it. Validation in the combined HOVON-50/ECOG study represents a pragmatic decision based on 
study size, study design, and our desire to identify penetrant variants that can be replicated with 
relevance to different studies and datasets.
Despite a comprehensive analysis of the genetic variation within the coagulation and pro-
thrombotic pathways, we could not find evidence for a significant association of genetic variation 
within these pathways with VTE risk following thalidomide exposure. Although we found Factor 
5 Leiden (rs6025) to be associated with an increased risk of VTE in this analysis, the thrombotic 
risk was not increased in patients treated with thalidomide; similar results were seen for poly-
morphisms in MTHFR and FGB. We saw no association with thalidomide related VTE in commonly 
reported VTE risk alleles in F2-455G/A (rs3136430) splice variant 20210G/A (rs3136431). We did 
find weak associations with genes known to mediate the coagulation pathway, including MTRR, 
PLAUR, PPARD, PPARGC1A, PPARGC1B, THBS4, and WNK, but the associated risk was not high. We 
conclude that we can exclude a major contribution of genetic variation within the coagulation 
and prothrombotic pathways based on this targeted approach, although smaller contributions 
to the phenotype may be missed because of the study size and design. Our findings are consis-
tent with previous clinical observations and work by some of the authors, who failed to identify 
relevant changes in functional assays investigating this pathway.65-67
The lack of a strong association with variation in the coagulation cascade suggests that VTE 
risk is mediated via alternative mechanisms. We identified the 18 SNPs, which validated across 
the 3 datasets (Figure 3). Using the whole BOAC panel as the background gene set in the DAVID 
Functional Annotation Clustering tool against the 18 validated genes, generated 3 major en-
riched annotation clusters. The annotation clusters consisted of 2 “response to stress” groups; 
a response to DNA damage group, including CHEK1, XRCC5, LIG1, ERCC6, DCLRE1B, and PARP1; a 
cytokine response group containing NFKB1, TNFRSF17, IL-12B, and LEP; and a third related group 
of “apoptosis” with CASP3, PPARD, and NFKB1. These enrichment groups indicate that genetic 
variation in response to DNA damage and cytokine mediated apoptosis modulates risk of devel-
oping a thalidomide related thrombosis.
High-dose dexamethasone enhances hemostasis, increases platelet activation, and promotes 
von Willebrand factor (vWF) antigen–dependent thrombosis.68 Extremely high levels of factor VIII 
coagulant (FVIII:C) activity and vWF have been found in thalidomide exposed patients.69 Patients 
67
that develop a subsequent VTE had higher vWF antigen (Ag) levels but not FVIII:C levels. High 
FVIII:C/vWF Ag levels are found in patients with active myeloma; this is probably a reflection 
of increased bone marrow angiogenesis in myeloma. These prothrombogenic circumstances
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Figure 4. Predictive tree of thalidomide related thrombosis in myeloma patients following recursive parti-
tioning analysis.
would contribute to VTE during treatment with a thalidomide-dexamethasone combination.69 
In line with vWF mediating the prothrombotic effects of dexamethasone in thalidomide related 
VTE, we saw a protective effect of vWF nonsynonymous SNP (rs216321) and synonymous SNP 
(rs216902) in thalidomide treated controls.
Although there is evidence to suggest thalidomide may damage DNA directly,70 it is important 
to note the majority of cases in this analysis were derived from the MRC and HOVON-50 studies, 
which included either cyclophosphamide or doxorubicin/adriamycin in the treatment regime, 
which may explain an association with DNA repair genes. Variation in DNA repair capacity could 
readily affect the response of the myeloma clone to treatment due to the direct relationship be-
tween the extent of DNA damage accumulation and the clinical response to alkylating agents.71 
A rapid response and dissolution of myeloma clones with an impaired double-stranded DNA 
repair pathway would release greater prothrombotic factors that could be either microparticles 
with surface tissue factor or cytokines and tissue factor. The greater thrombogenesis due to in-
creased dissolution of the myeloma clone may act additively with a dexamethasone-thalidomide 
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interaction on plasma cells,72 giving rise to an increased number of VTEs in the MRC and HOVON 
studies.73-74 An alternative mechanism to explain the increased risk of a VTE associated with DNA 
repair genes could be based on the observation that thalidomide can protect endothelial cells 
from doxorubicin induced apoptosis by restoring PAR-1 expression,75 promoting subendothe-
lial tissue factor exposure, endothelial dysfunction, and platelet activation, and consequently 
increasing the thrombosis risk.75-77 Under these conditions, decreased DNA repair capacity could 
promote clot formation at the endothelium (Figure 5).
TF TF
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Figure 5. Thalidomide treatment in combination with alkylating agents in myeloma promotes prothrom-
botic conditions at the endothelium surface via a combination of mechanisms. Mechanisms include rapid 
apoptosis of myeloma cells leading to circulating tissue factor (TF), exposed TF by endothelium cells salvaged 
from apoptosis, increased circulating cytokines (e.g., TNFα) with T cell activation by antigen-presenting cells 
(APCs), and activated platelets in response to increased circulating cytokines.
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The enrichment of cytokine mediated apoptosis genes in SNPs associated with thalidomide 
related thrombosis risk may also give clues to the role bortezomib and aspirin play in VTE 
management. Low rates of VTE are seen in patients with myeloma treated with bortezomib in 
thalidomide combinations,37,40,78 possibly through the prevention of the upregulation of pro-
thrombotic molecules such as thrombomodulin, cytokines, and E-selectin by bortezomib.79-80 A 
number of clinical studies have suggested that aspirin42,81-89 is effective at preventing the excess 
of VTE seen in thalidomide exposed individuals. Aspirin is classically thought to inhibit platelet 
COX-2, reducing platelet adhesiveness and modulating risk of arterial thrombosis. Aspirin can 
also lead to decreased levels of circulating TNFα by inhibiting IKK and therefore NFκB. Higher 
levels of TNFα and COX-2 lead to an increased risk of apoptosis in endothelial cells, which also 
become proadhesive to nonactivated platelets.90 In a thalidomide treatment setting, aspirin may 
be able to inhibit thalidomide VTE mediated events by lowering circulating TNFα.
Genetic analysis of the multifactorial phenotype that is thalidomide related venous throm-
bosis is challenging. To minimize experimental artifacts that can be found in many association 
studies,91 we have associated a discrete clinical outcome from a homogenous population of simi-
larly treated patients with high-quality genotype data with stringent quality controls. We took 
a hypothesis-driven candidate gene approach rather than a whole genome scan (WGS)–based 
approach because it was clear that the number of events to be analyzed would be small, and 
we were aiming to identify pertinent functional loci variants with moderate to large effect size. 
We accept that future GWS and sequencing approaches may add relevant variants in unknown 
pathways. As part of the analysis, we took an exploratory approach to defining whether the 
SNPs identified could be used to identify patients at high risk of VTE and consequently guide 
clinical intervention. Guidelines have recently been established to govern clinical indicators for 
intervention, but these prognostic factors can be difficult to identify and use clinically.41 The US 
Food and Drug Administration (FDA) and European Medicines Evaluation Agency (EMEA) have 
published warnings suggesting the use of thromboprophylaxis with any immunomodulatory 
derivative of thalidomide (IMiD)–based regimen.92-94 The results of this recursive partitioning 
analysis have identified a limited number of SNPs that, when analyzed together, can predict the 
risk of VTE. Testing for these SNPs has the potential for being clinically useful for identifying 
high-risk patients for whom therapeutic intervention is required. For clinically defined high-risk 
patients intervention strategies may not change, but for patients at genetic high risk for whom 
aspirin was the chosen strategy, intervention with warfarin or LMWH would be more appropriate.
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Abstract
Purpose
To indentify genetic variation that can modulate and predict the risk of developing thalidomide 
related peripheral neuropathy (TrPN).
Patients and methods
We analyzed DNA from 1512 patients with multiple myeloma. Using a custom-built single 
nucleotide polymorphism (SNP) array, we tested the association of TrPN with 3404 SNPs. The 
SNPs were selected in predicted functional regions within 964 genes spanning 67 molecular 
pathways thought to be involved in the pathogenesis, treatment response and side effects as-
sociated with myeloma and its therapy. Cases and controls were derived from two large clinical 
trials that compared thalidomide with conventional based treatment in myeloma patients; MRC 
Myeloma-IX and HOVON-50/GMMG-HD3.
Results 
We report TrPN associations with SNPs: ABCA1 (rs363717), ICAM1 (rs1799969), PPARD (rs2076169), 
SERPINB2 (rs6103) and SLC12A6 (rs7164902), where we show cross validation of the associations 
in both trials. To investigate whether TrPN SNP associations were related to exposure to thalido-
mide only or general drug related peripheral neuropathy, we performed a second analysis on 
patients treated with vincristine. We report SNPs associated with vincristine neuropathy, with a 
seemingly distinct underlying genetic mechanism.
Conclusion
Our results are consistent with the hypothesis that an individual’s risk of developing a periph-
eral neuropathy following thalidomide treatment can be mediated by polymorphisms in genes 
governing repair mechanisms and inflammation in the peripheral nervous system. These find-
ings will contribute to the development of future neuro-protective strategies with thalidomide 
therapy and the better use of this important compound.
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Introduction
Peripheral neuropathy is a significant adverse event in multiple myeloma patients treated with 
thalidomide. Thalidomide related peripheral neuropathy (TrPN) typically consists of symmetrical 
paresthesias, with loss of tactile and pain response as well as numbness and muscle cramps.1 
Rates of neuropathy following thalidomide treatment vary from 15-70%, with the risk of neu-
ropathy being related to the cumulative dose and duration of therapy.2-6 Factors influencing the 
risk of neurotoxicity include prior neuropathy, age,7 previous chemotherapy, and vitamin B12 
and/or folate deficicency.8 The mainstay of TrPN prevention is dose reduction or withdrawal of 
thalidomide, which can lead to symptom resolution in up to 16 weeks,9 however in some cases 
neuropathy is irreversible. 
At a pathologic level, TrPN is a length-dependent, predominantly sensory axonal neuropathy 
affecting large and small fibers,1,5 but has also been classified as a ganglionopathy.5,10 Reduction 
in amplitude or absence of sensory nerve action potentials is the most common electrophysi-
ological alteration that can precede symptoms or worsen after thalidomide withdrawal and of-
ten does not resolve.6,11 Proposed mechanisms to explain TrPN include; anti-angiogenesis, direct 
toxic effects on the posterior root ganglia and dysregulation of neurotrophin activity through 
NFκB. 
To date there have been only a limited number of small studies investigating the genetic fac-
tors that associate  with TrPN.12-13 In this study we have sought to address this by investigating 
the genetic variation associated with risk of TrPN in two large clinical trials, consisting of patients 
treated with thalidomide or vincristine and genotyped with a custom targeted panel of 3404 
SNPs.
 
Materials and methods 
Clinical samples
Peripheral blood DNA samples were obtained from 1512 presenting multiple myeloma cases 
derived from two randomized clinical trials; Medical Research Council (MRC) Myeloma-IX study 
(n=993), and the HOVON-50/GMMG-HD3 (n=519), comparing standard treatment to thalido-
mide containing regimens. Peripheral neuropathy was assessed using National Cancer Institute 
(NCI) Common Toxicity Criteria version 2.0. Neuropathy events were only considered following 
induction therapy and not during maintenance. In a discovery set analysis we compared geno-
type results from 194 Myeloma-IX patients with neuropathy following exposure to thalidomide, 
with 416 control patients treated with thalidomide that did not develop neuropathy. Cases and 
controls were matched for age and sex. As validation we carried out a comparison using 74 
thalidomide treated patients with neuropathy from the HOVON-50/GMMG-HD3 trial, with 176 
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thalidomide treated controls. We then carried out a comparison using cases of neuropathy grade 
≥ 2 in the Myeloma-IX dataset; 75 cases with neuropathy were compared with 297 matched 
controls. The HOVON-50/GMMG-HD3 analysis contained 49 neuropathy ≥ 2 cases with 176 con-
trols. In the non-thalidomide arms, neuropathy events were also observed following vincristine 
exposure. We carried out a nested case-control comparison using 76 cases of vincristine related 
neuropathy from the Myeloma-IX trial compared to 307 controls. In the HOVON-50/GMMG-HD3 
cohort we compared genotypes from 26 vincristine related neuropathy cases with 226 controls. 
To ensure homogeneity of allelic frequencies, only patients of European descent were included. 
Clinical trials
The Myeloma IX study comprises 2 randomizations: an intensive pathway for younger, fitter 
patients comparing CVAD (cyclophosphamide 500 mg orally weekly, vincristine 0.4 mg intra-
venously on days [d] 1-4), doxorubicin 9.0 mg/m2 on d1-d4, dexamethasone 40 mg on d1-d4 
and d12-d15), delivered by a central venous access device with oral CTD (cyclophosphamide, 
thalidomide, dexamethasone) using the same doses of cyclophosphamide and dexamethasone 
combined with 200 mg of thalidomide. The second randomization, for older, less-fit patients, 
compared an attenuated dose of CTD (thalidomide 100-200 mg) to melphalan (7.0 mg/m2 orally 
on d1-d4 every 28 days) and prednisolone (MP). The HOVON-50/GMMG-HD3 study randomized 
patients to either: 3 cycles of VAD (vincristine (0.4 mg, intravenously rapid infusion on d1-d4), 
doxorubicin (9 mg/m2, intravenously rapid infusion on d1-d4) and dexamethasone (40 mg orally, 
d1-d4, d9-d12, and d17-d20)) or the same regimen but with thalidomide (TAD; 200 mg, but could 
be escalated to 400 mg), replacing the vincristine (Figure 1A).
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Figure 1. (A) Simplified treatment arms of the Myeloma-IX and HOVON-50/GMMG-HD3 trials. (B) Case and 
control comparisons used in SNP analysis for patients from the Myeloma-IX and HOVON-50/GMMG-HD3 tri-
als.
Genotyping and SNP selection 
DNA was extracted from frozen white blood cell pellets using Flexigene kit (Qiagen, Crawley, UK) 
and quantified using a Nanodrop® Spectrophotometer (Nanodrop products, Wilmington, USA). 
Genotyping was performed using an Affymetrix Targeted genotyping True-tag Bank On A Cure 
(BOAC) array.14-16 SNPs were selected using a hypothesis-driven strategy, targeting genes and 
SNPs with previously described associations or putative functional effects. There was no sample 
ascertainment bias between cases and controls, as genotyping was performed before access to 
demographic and phenotypic data.
Statistical analyses
Departures from Fisher Exact Hardy-Weinberg equilibrium at a P level less than 10-5 and bias in 
missing data were controlled for each SNP. A Cochran-Armitage trend test and a Fishers Exact 
test were performed to evaluate odds ratios. Genomic inflation factor λ was evaluated based on 
median chi-squared for each set of analyses. To account for multiple testing we carried out label 
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swapping permutation procedures on each SNP. Proxy association testing was performed where 
multiple SNPs in a gene were found to be associated, to resolve haplotypes. Association analysis 
was performed using the program PLINK v1.07.17 DAVID Bioinformatics Resource18 was used to 
characterize pathways enriched in risk associated genes.
The functional impact of regulatory SNPs in association with TrPN, was investigated by ensur-
ing the gene was typically expressed in neurons,19 and then subsequently examining myeloma 
tumor expression data in relation to SNP genotype using a Wilcoxon-type test for trend.20-21
To generate a predictive strategy based on genetic variation, recursive partitioning analysis 
was performed using the program Willows.22 Redundant associated SNPs in linkage disequilib-
rium (LD) were filtered and recursive partitioning was performed on a training set consisting of 
two-thirds of the Myeloma-IX dataset to create an initial predictive tree, this tree was “pruned” 
at level of P < 0.001, to a smaller number of classifier SNPs. The final predictive tree was then 
assessed for its ability to correctly classify the remaining one-third of the Myeloma-IX and 
HOVON-50/GMMG-HD3 datasets. 
In an alternate approach, a “risk score classifier” was generated based on the summation of the 
associated “at risk” and “protective” SNPs. Using a training set of two-thirds of the Myeloma-IX 
dataset, the log10 (odds ratios) of the associated SNPs for each patient was summed. This scoring 
system was assessed for its ability to correctly classify patients “at risk” in the remaining one-third 
of the Myeloma-IX and HOVON-50/GMMG-HD3 datasets.
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Table 1. Clinical demographics of patients within the Myeloma-IX study.
Cases with neuropathy % Controls without neuropathy %
Thalidomide All neuropathy 192 31.8 416 68.2
 > grade 2 neuropathy 76 12.5 416 68.2
Sensory neuropathy 91 69.1 NA NA
Sensory and motor 
neuropathy
28 14.4 NA NA
Motor neuropathy 27 16.5 NA NA
Sex 135 males 69.6 (males) 225 males 54 (males)
59 females 31.4 (females) 191 females 46 (females)
Median age 62 years NA 65 years NA
Median cycles of 
thalidomide
5 NA 5 NA
Median time to  
neuropathy (weeks)
8 NA NA NA
ISS 1 34 23.6 84 27.2
2 54 37.5 121 39.2
3 56 38.9 104 33.7
Paraprotein type IgG 107 55.7 243 58.4
IgA 46 24 82 19.7
IgM 2 1 2 0.4
IgD 4 2 9 0.8
Light chain only 17 8.9 56 13.4
Missing data 16 8.3 24 5.7
FISH status IgH translocation 52/115 45.2 116/241 48.1
Hyperdiploidy 60/114 52.6 122/229 53.2
t(4;14) 12/115 10.4 31/237 13
t(11;14) 14/115 12.2 33/237 14
Deletion 1p32.1 12/92 13 26/202 12.9
Gain 1q21 33/99 33.3 72/205 35.1
Vincristine All neuropathy 76 19.8 307 NA
 > Grade 2 neuropathy 31 40.7 307 NA
Median time to  
neuropathy (weeks)
8 NA NA NA
No thalidomide All neuropathy 19 7.6 231 NA
or vincristine  > Grade 2 neuropathy 7 2.8 231 NA
Median time to  
neuropathy (weeks)
6 NA NA NA
NA indicates not applicable.
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Results
Clinical results
The clinical demographics of the Myeloma-IX trial patients across the whole trial (Table 1) were 
comparable to the samples derived from it in the case-control comparison (Table S1), and 
included 970 cases treated with CTD and 550 with CVAD (Figure 1B). In this analysis 31.8% of 
patients developed neuropathy, with grade ≥ 1, 11% grade ≥ 2, and 3.6% grade ≥ 3, following ex-
posure to thalidomide. The median time to neuropathy was eight weeks. A higher frequency of 
grade ≥ 3 was seen in older patients, at 5%. In patients exposed to vincristine, 33.6% developed 
neuropathy in a median of eight weeks. In contrast, 6.4% patients not exposed to thalidomide 
or vincristine, developed grade 1 neuropathy in a median time of six weeks (Table S2). We did 
not see significant differences between patients with and without neuropathy for previously 
described risk factors such as immunoglobulin type, and age.7 Assessing the rates of TrPN based 
on the ISS stage, we show that tumor burden is not related to risk. Similarly, as fluorescence 
in situ hybridization (FISH) variants are distributed evenly between patients with and without 
neuropathy, the pathogenic subtype does not seem to contribute to risk. Interestingly, we 
identified increased rates in male cases compared to females, the cause for which is uncertain. 
In order to address the hypothesis that patients who respond best to thalidomide are more 
sensitive to TrPN, we examined the relationship of neuropathy to response during induction 
in the Myeloma-IX study. While we saw a greater percentage of complete responses (CR) and 
very good partial responses (VGPR) in patients lacking neuropathy, the difference did not reach 
statistical significance (Pearson Chi-square test, P = 0.55; Figure 2A). Additionally, we did not see 
a significant relationship between response and time to neuropathy (Figure 2B). These clinical 
data show the variability of risk between patients and the lack of any simple clinical variants that 
can predict risk. 
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Figure 2. (A) Response status versus neuropathy during induction therapy in the Myeloma-IX study. (B) Time 
to neuropathy in relation to response during induction therapy with thalidomide in the Myeloma-IX study.
Genotyping results
To address the hypothesis that genetic variation mediates the risk of TrPN we compared the 
genetic contribution to cases that developed neuropathy with those who did not. The initial 
analysis included all TrPN cases and a secondary analysis was carried out using only neuropathy 
of grade ≥ 2. SNPs significantly associated with TrPN (P < 0.01) in the Myeloma-IX dataset are 
shown in Table 2. The associated SNPs were similar in grade ≥ 1 and grade ≥ 2 analyses, indicat-
ing a common mechanism for thalidomide neuropathy across the groups. 
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Table 2. SNP associations with thalidomide related neuropathy (grade ≥ 2) in the Myeloma-IX study, using a 
Trend test for association, permutated P < 0.01. The genomic inflation factor λ is 1.0.
SNP Chr Alleles
Odds ratios Fishers 
Exact (95% CI) P for Trend Gene SNP type
rs246220 16 G > C 0.49 (0.33-0.73) < 0.001 ABCC1 Intron,TagSNP:ABCC1
rs7164902 15 A > G 0.60 (0.44-0.80) 0.001 SLC12A6 Coding-synonymous
rs1805386 13 G > A 0.56 (0.39-0.79) 0.001 LIG4 Coding-synonymous
rs3740066 10 T > C 1.51 (1.18-1.93) 0.001 ABCC2 Coding-synonymous
rs4752904 11 G > C 0.69 (0.54-0.88) 0.002 PTPRJ Coding-nonsynonymous
rs8192341 8 A > C 1.48 (1.14-1.93) 0.003 SFTPC Coding-nonsynonymous
rs2292334 6 A > G 0.71 (0.55-0.91) 0.004 SLC22A3 Coding-synonymous
rs246 11 A > G 1.54 (1.15-2.07) 0.005 CYP2C9 Intron
rs4839469 1 A > G 1.56 (1.13-2.15) 0.005 VANGL1 Coding-nonsynonymous
rs3735481 7 A > C 1.50 (1.12-2.00) 0.006 PPIA Intron
rs2272037 15 T > C 1.40 (1.10-1.78) 0.007 IGF1R Intron
rs231775 2 G > A 1.38 (1.08-1.77) 0.007 CTLA4 Coding-nonsynonymous
rs914959 1 T > C 0.70 (0.54-0.90) 0.007 DPYD Intron,TagSNP:DPYD
rs3136794 8 G > A 1.62 (1.15-2.29) 0.009 POLB Intron
SNP indicates single nucleotide polymorphism; Chr, chromosome; CI, confidence interval.
Findings from the Myeloma-IX study were validated in a second comparable trial; HOVON-50/
GMMG-HD3, and significantly associated SNPs in this study are shown in Table S2 and S4. In 
order to cross validate the findings between the trials, we investigated whether a significantly 
associated SNP in either trial alone (permutated P ≤ 0.05) was associated with risk in the second 
trial. This included 103 SNPs from the Myeloma IX and 82 SNPs from HOVON-50/GMMG-HD3. 
Using this approach on TrPN grade ≥ 2, we found five cross validating SNPs in different genes 
(Table 3).  It should be noted however, that the size of the validation set may be under powered 
to validate all associations in the discovery set. Associated regulatory region SNPs were analyzed 
for a relationship with gene expression (Figure S1).
Table 3. SNP associations with thalidomide related neuropathy (grade ≥ 2) associated in both the Myeloma-IX 
and HOVON-50/GMMG-HD3 trials, using a Trend test for association, permutated P < 0.05.
(UK- Myeloma IX) (Dutch- HOVON-50)
SNP Chr Alleles
Odds ratios
Fishers Exact 
(95% CI)
Permutated 
P for Trend
Odds ratios
Fishers Exact 
(95%CI)
Permutated 
P for Trend Gene SNP Type
rs7164902 15 A > G 0.60 (0.44-0.80) < 0.001 0.47 (0.25-0.87) 0.023 SLC12A6 Coding-synonymous
rs6103 18 G > C 0.70 (0.52-0.95) 0.018 0.56 (0.30-1.07) 0.054 SERPINB2 Coding-nonsynonymous
rs2076169 6 G > A 0.60 (0.38-0.95) 0.026 0.27 (0.08-0.90) 0.025 PPARD Intron
rs363717 9 C > T 0.71 (0.52-0.98) 0.041 0.46 (0.22-0.97) 0.045 ABCA1 Untranslated
rs1799969 19 A > G 0.67 (0.44-1.03) 0.050 0.40 (0.15-1.04) 0.046 ICAM1 Coding-nonsynonymous
SNP indicates single nucleotide polymorphism; Chr, chromosome; CI, confidence interval.
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Haplotype analysis of ABCC1 variants with TrPN, reveal that the main effect can be attributed 
to a two SNP haplotype involving SNPs rs246217 and rs246218 (Figure S2). Analysis of the 12 
genotyped SNPs in the ABCC2 gene reveal a four SNP haplotype, with three SNPs additively 
contributing to risk of TrPN (Figure S3).
To investigate whether the observed associations with thalidomide were drug specific, we 
sought to contrast findings with vincristine treated patients. SNPs significantly associated with 
vincristine related neuropathy in the Myeloma-IX dataset are shown in (Table 4, S3, and S4).  
Table 4. SNP associations with vincristine related neuropathy (grade ≥ 2) associated in both the Myeloma-IX 
and HOVON-50/GMMG-HD3 trials, using a Trend test for association, permutated P < 0.05.
(UK- Myeloma IX) (Dutch- HOVON-50)
SNP Chr Alleles
Odds ratios
Fishers Exact (95% CI)
Permutated
P for Trend
Odds ratios
Fishers Exact (95%CI)
Permutated
P for Trend Gene SNP type
rs7242 7 G > T 1.88 (1.17-3.01) 0.006 2.15 (1.15-4.00) 0.015 SERPINE1 Untranslated
rs2082382 5 G > A 0.50 (0.30-0.83) 0.009 0.52 (0.27-1.02) 0.051 ADRB2 Promoter
rs1555026 1 C > T 2.73 (1.29-5.76) 0.009 2.45 (0.95-6.30) 0.049 ID3 Locus
rs1042714 5 G > C 0.51 (0.31-0.85) 0.010 0.52 (0.27-1.01) 0.047 ADRB2 Coding-nonsynonymous
rs1934951 10 T > C 1.90 (1.14-3.16) 0.012 2.36 (1.20-4.65) 0.016 CYP2C9 Intron
rs7214723 17 C > T 1.70 (1.06-2.71) 0.020 1.90 (1.03-3.51) 0.038 CAMKK1 Coding-nonsynonymous
rs1058932 10 A > G 1.74 (1.04-2.89) 0.027 2.18 (1.11-4.30) 0.024 CYP2C8 Untranslated
rs2301157 13 A > G 0.61 (0.38-1.00) 0.039 0.52 (0.27-0.98) 0.035 SLC10A2 Untranslated
rs228832 20 T > C 0.51 (0.27-0.96) 0.040 0.39 (0.16-0.94) 0.030 NFATC2 Intron
SNP indicates single nucleotide polymorphism; Chr, chromosome; CI, confidence interval.
Using inherited genetic variation as a clinical means of risk stratification to adjust thalidomide 
dose is an important clinical goal. In an effort to build a predictive model based on a limited 
number of predictive SNPs, we examined two classification methods. In the first method, we 
utilized recursive partitioning to create a predictive tree. This tree predicted cases and controls 
with a sensitivity of 38% and a specificity of 31% in the Myeloma-IX validation set, and a sensitiv-
ity of 30.7% and a specificity of 81.6% in HOVON-50/GMMG-HD3 dataset (Figure S4). The second 
method; cumulative risk score, predicted cases of neuropathy with a sensitivity of 100% and a 
specificity of 77.8% in the Myeloma IX validation, and sensitivity of 60% and a specificity of 70.5% 
in HOVON-50/GMMG-HD3 dataset (Figure S5).
Discussion
Using a hypothesis-driven candidate gene approach we show for the first time that there is a 
significant genetic contribution to the risk of TrPN. Thalidomide is used in the treatment of a 
number of diseases where the increased production of TNFα is thought to be pathogenically 
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important, but the benefits of thalidomide can be limited by the onset of TrPN. This study, the 
largest of its kind to date, has allowed us to identify genetic variants that contribute to TrPN risk. 
These findings provide important insights into the therapeutic management of these patients 
and will stimulate further research into protective strategies for patients treated with thalido-
mide. While we considered taking a genome-wide approach to identify such genetic variation, 
this was not applicable because of issues with statistical power. In addition, the candidate gene 
approach allowed us to examine our candidate regions in greater detail than could be achieved 
with mapping arrays such as the Affymetrix 500K or Illumina 550K. 
The doses of thalidomide used in the study were moderate at 100-200 mg, and the neuropa-
thy occurred early, after a median of 3 cycles of treatment. This group of cases is distinct from 
the group who develop neuropathy associated with prolonged exposure, which is dependent 
on the total dose of thalidomide received and was not studied here. We did not identify a clini-
cal parameter which was associated with early onset neuropathy and patients were not unduly 
sensitive to thalidomide, with response rates being similar in cases and controls.  We cannot be 
certain about associations with other co-morbid conditions such as diabetes, diet and alcohol 
consumption as the data were not systematically collected. Cases with pre-existing neuropathy 
were excluded.  
A number of ATP-Binding Cassette (ABC) transporters genes were linked with TrPN.  Both ABCC1 
SNPs rs246217 and rs246218 are intronic, but lie within transcription binding domains and may 
mediate levels of expression of ABCC1. Two SNPs in ABCC2 ((rs3740066) and (-24) C > T (rs717620)) 
are also associated with neuropathy risk. rs717620 has been associated with decreased ABCC2 
function in vitro23-25 and toxicity in other systems,26 whereas rs3740066 may modulate substrate 
specificity via codon usage therefore influencing the translation rate.27  Also, in ABCA1 rs363717 
is a cross validating SNP and is found in the binding domain of the microRNA, hsa-miRNA-299. 
Weaker associations were also seen with ABCB1 and its role in mediating peripheral neuropathy 
in response to taxane exposure has been previously reported.28-29 Interestingly, thalidomide can 
modulate the function of ABCC2 and ABCB1,30 both of which are active in neuronal function.
We saw a number of associations with other absorption, distribution, metabolism, excretion 
(ADME) genes, including a promoter SNP in FMO6 (rs1736565) and the ion channel gene SLC12A6 
(rs7614902), previously associated with peripheral neuropathy.31 It has been suggested that 
CYP2C19 plays a role in thalidomide metabolism,32-34 however, it is now known that thalidomide 
breakdown is dependent on spontaneous non-enzymatic degradation.35 Consistent with this we 
found no association of neuropathy risk with functional variants in CYP2C19, or other genes in 
the CYP2C subfamily. No consistent association was seen with common N-acetyltransferase 2 
(NAT2) variants, as previously reported.13 
Pathway analysis of the TrPN associated SNPs highlights the association with genes involved 
in the development of the central and peripheral nervous system. A conserved promoter SNP 
(rs1611753), which affects the expression of the gene SPRR1A, was significantly associated with 
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TrPN in HOVON-50/GMMG-HD3 samples. The gene SPRR1A is expressed by axotomized neurons 
and promotes axonal outgrowth.36 Variation in neurological genes may dictate the ability of a 
damaged neuron to undergo repair and may mediate risk of neuropathy. 
We also describe associations with SNPs in genes mediating neuro-inflammation, with some 
35% of the TrPN associated SNPs having an inflammatory role. We see associations with SERPINB2 
(rs6103), a gene induced in injured neurons37 and PPARD (rs2076169) which may also indicate a 
role of neuro-inflammation in the pathology mechanism. 
We found 20% of the TrPN associated genes in this study to have some transmembrane trans-
porter activity, consistent with a hypothesis where variants in transmembrane transporter genes 
mediate their effects at the level of the peripheral nerve.38 At this site, they negatively impact the 
ability of the dorsal root ganglions to repair itself following exposure to the toxic effects of tha-
lidomide and/or promote neuro-inflammatory change. Prophylactic pharmacological therapies 
aimed at modulating ion channel activity may prove useful in reducing neuro-toxicity caused by 
axonal membrane ion channel variation.39-40 
The genetic mechanisms underlying thalidomide and vincristine neuropathy appear distinct. 
SNP associations with vincristine related neuropathy include rs2082382 and rs1042714 in ADRB2. 
Association with vincristine related neuropathy was observed in a highly conserved promoter 
SNP (rs7214723) in CAMKK1, which is expressed at higher levels in neurons resistant to oxida-
tive stress. We also see an association with nonsynonymous SNPs in CYP2C9 (rs1934951) and 
NFATC2 (rs228832), conserved intronic SNPs in ID3 (rs1555026) and SLC10A2 (rs2301157), and in 
CYP2C8 (rs1058932) which is located in the binding site for the microRNA hsa-miRNA-96. Inter-
estingly, we see little overlap of the genes associated with TrPN in comparison with vincristine 
related neuropathy. We propose that this is indicative of a fundamentally different pathological 
mechanism between these neuropathies. In contrast, similar TrPN associated genes have been 
observed in studies investigating peripheral neuropathy in response to paclitaxel, bortezomib 
and docetaxel which result in sensory peripheral neuropathies as opposed to the sensorimotor 
neuropathy associated with exposure to the vinca alkaloids and taxol. 
We show that simple clinical factors do not allow the identification of patients at greater 
risk of neuropathy following thalidomide exposure, for which dose adjustment or cessation of 
therapy would be appropriate. Consequently, we have attempted to define a limited number of 
SNPs that can identify high risk patients suitable for more intensive clinical monitoring. In this 
approach, we have used two risk classification methods both of which can identify patients at 
increased risk, but the predictive value of these is not adequate to totally avoid thalidomide us-
age. However, this approach can be used to identify patients requiring greater clinical vigilance 
and suitable counseling. 
The poor risk prediction in our classifiers is due to a number of limitations, which include; a) 
naive assumptions in modeling methods, the risk score method assumes interactions to be solely 
additive, whilst recursive partitioning method interactions are assumed to be uni-directional, 
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b) hypothesis-driven approaches do not consider all variation contributing to an outcome, c) 
population specific effects, and d) the impact of rare variation. Despite these drawbacks, the 
limited number of SNPs identified in this study can be used as a simple and useful method for 
identifying patients at high risk of TrPN, who in turn may benefit from greater clinical vigilance.
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Summary
Background
Bortezomib induced peripheral neuropathy is a dose-limiting toxicity in patients with multiple 
myeloma, often requiring adjustment of treatment and affecting quality of life. We investigated 
the molecular profiles of early onset (within one treatment cycle) versus late onset (after two or 
three treatment cycles) bortezomib induced peripheral neuropathy and compared them with 
those of vincristine induced peripheral neuropathy during the induction phase of a prospective 
phase 3 trial.
Methods 
In the induction phase of the HOVON-65/GMMG-HD4 trial, patients (aged 18–65 years) with 
newly diagnosed Salmon and Durie stage 2 or 3 multiple myeloma were randomly assigned to 
three cycles of bortezomib-based or vincristine-based induction treatment. We analyzed the 
gene expression profiles and single nucleotide polymorphisms (SNPs) of pretreatment samples 
of myeloma plasma cells and peripheral blood, respectively. This study is registered, number 
ISRCTN64455289.
Findings 
We analyzed gene expression profiles of myeloma plasma cells from 329 (39%) of 833 patients 
at diagnosis, and SNPs in DNA samples from 369 (44%) patients. Early onset bortezomib induced 
peripheral neuropathy was noted in 20 (8%) patients, and 63 (25%) developed the late onset type. 
Early onset and late onset vincristine induced peripheral neuropathy was noted in 11 (4%) and 
17 (7%) patients, respectively. Significant genes in myeloma plasma cells from patients that were 
associated with early onset bortezomib induced peripheral neuropathy were the enzyme coding 
genes RHOBTB2 (upregulated by 1.59 times; P = 4.5 x 10-⁵), involved in drug-induced apoptosis, 
CPT1C (1.44 times; P = 2.9 x 10-⁷), involved in mitochondrial dysfunction, and SOX8 (1.68 times; 
P = 4.28 x 10-¹³), involved in development of peripheral nervous system. Significant SNPs in the 
same patients included those located in the apoptosis gene caspase 9 (odds ratio [OR] 3.59, 95% 
CI 1.59–8.14; P = 2.9 x 10-³), ALOX12 (3.50, 1.47–8.32; P = 3.8 x 10-³), and IGF1R (0.22, 0.07–0.77; P 
= 8.3 x 10-³). In late onset bortezomib induced peripheral neuropathy, the significant genes were 
SOD2 (upregulated by 1.18 times; P = 9.6 x 10-³) and MYO5A (1.93 times; P = 3.2 x 10-²), involved in 
development and function of the nervous system. Significant SNPs were noted in inflammatory 
genes MBL2 (OR 0.49, 95% CI 0.26–0.94; P = 3.0 x 10-²) and PPARD (0.35, 0.15–0.83; P = 9.1 x 10-³), 
and DNA repair genes ERCC4 (2.74, 1.56–4.84; P = 1.0 x 10-³) and ERCC3 (1.26, 0.75–2.12; P = 3.3 
x 10-³). By contrast, early onset vincristine induced peripheral neuropathy was characterized by 
upregulation of genes involved in cell cycle and proliferation, including AURKA (3.31 times; P = 
1.04 x 10-²) and MKI67 (3.66 times; P = 1.82 x 10-³), and the presence of SNPs in genes involved 
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in these processes - e.g., GLI1 (rs2228224 [0.13, 0.02–0.97, P = 1.18 x 10-²] and rs2242578 [0.14, 
0.02–1.12, P = 3.00 x 10-²]). Late onset vincristine induced peripheral neuropathy was associ-
ated with the presence of SNPs in genes involved in absorption, distribution, metabolism, and 
excretion - e.g., rs1413239 in DPYD (3.29, 1.47–7.37, 5.40 x 10-³) and rs3887412 in ABCC1 (3.36, 
1.47–7.67, P = 5.70 x 10-³).
Interpretation
Our results strongly suggest an interaction between myeloma related factors and the patient’s 
genetic background in the development of treatment induced peripheral neuropathy, with 
different molecular pathways being implicated in bortezomib induced and vincristine induced 
peripheral neuropathy. 
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Introduction
Bortezomib (Millennium Pharmaceuticals, Cambridge, MA, USA) is a boronic acid dipeptide, 
which specifically inhibits the chymotryptic site of the 26S proteasome. In patients with newly 
diagnosed myeloma, bortezomib in combination with conventional drugs resulted in high rates 
of complete response and very good partial response.1–4 This drug is generally well tolerated; 
however, one of its most frequent and potentially disabling side effects is the development of 
a painful, sensory peripheral neuropathy,5–7 often requiring dose modification or discontinua-
tion of bortezomib, which negatively affects clinical endpoints and quality of life.8 Grade 1 and 
2 bortezomib induced peripheral neuropathy can arise in 27–75% of patients with recurrent 
multiple myeloma and in 25–33% of those with newly diagnosed multiple myeloma, whereas 
grade 3 and 4 peripheral neuropathy might affect 0–30% of patients with recurrent disease and 
0–18% of those with newly diagnosed disease.9 In most patients, this side effect is reversible 
and does not seem to be affected by the number or type of previous treatments.7 Bortezomib 
induced peripheral neuropathy results from axonal degeneration,10,11 often occurring within the 
first cycles of treatment, and does not seem to increase after the fifth cycle of bortezomib.7
Little is known about the mechanism of bortezomib induced peripheral neuropathy, but a 
multifactorial pathogenesis seems likely. Damage to mitochondria and endoplasmic reticulum 
through activation of apoptosis has been seen in dorsal root ganglia of mice given bortezomib.11 
Additionally, mechanisms such as dysregulation of mitochondrial calcium homoeostasis,12 auto-
immune factors and inflammation,13 and blockade of nerve-growth-factor-mediated neuronal 
survival through inhibition of the activation of nuclear factor kappa B (NFκB)6 could contribute to 
bortezomib induced peripheral neuropathy. Evidence that multiple myeloma is also implicated 
in peripheral neuropathy was described by Ropper and Gorson14 in 1998. Baseline neuropathy is 
present in 15–20% of patients with newly diagnosed myeloma,15,16 which might be of both axo-
nal and demyelinating subtypes.14 The role of myeloma related factors in peripheral neuropathy 
related to treatment is not clear. Bortezomib induced peripheral neuropathy was noted at higher 
frequencies in patients with multiple myeloma than in those with solid tumors.17 Richardson and 
colleagues16 characterized the possible role of myeloma related factors in bortezomib induced 
peripheral neuropathy using plasma cells from patients with multiple myeloma. Additionally, we 
have noted that inherited single nucleotide polymorphisms (SNPs) are associated with a higher 
probability of developing thalidomide induced or bortezomib induced peripheral neuropathy 
(Corthals SL, unpublished data). We therefore analyzed myeloma related gene expression and 
inherited patient variations as indicators of the potential risk of developing treatment related 
peripheral neuropathy. We investigated whether particular molecular profiles were specific for 
early onset versus late onset bortezomib induced peripheral neuropathy and compared these 
with genetic profiles associated with early onset versus late onset vincristine induced peripheral 
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neuropathy to elucidate molecular differences associated with the development of peripheral 
neuro pathy after the different treatments.
 
Methods
Patients
833 patients (aged 18–65 years) with newly diagnosed Salmon and Durie stage 2–3 multiple 
myeloma were enrolled in a prospective, randomized phase 3 trial (HOVON-65/GMMG-HD4; 
EudraCTnr2004-000944-26) in 75 centers in The Netherlands, Germany, and Belgium.3 Patients 
were excluded if they had amyloidosis or monoclonal gammopathy of unknown significance, 
and baseline peripheral neuropathy of grade 2 or more. 
The trial was done in accordance with the Declaration of Helsinki, and was approved by a 
medical ethics review committee. We obtained written informed consent from the patients for 
treatment and sample procurement.
Procedures
Patients were randomly assigned to three cycles of induction treatment with vincristine 0.4 mg 
intra venously on days 1–4, doxorubicin 9 mg/m² intravenously on days 1–4, and dexamethasone 
40 mg orally on days 1–4, 9–12, and 17–20 or bortezomib 1.3 mg/m² intravenously on days 1, 4, 
8, and 11, doxorubicin 9 mg/m² intravenously on days 1–4, and dexamethasone 40 mg orally on 
days 1–4, 9–12, and 17–20. Stem cells were mobilized by use of cyclophosphamide 1000 mg/
m² intravenously on day 1, doxorubicin 15 mg/m² intravenously on days 1–4, dexamethasone 
40 mg orally on days 1–4, and granulocyte colony-stimulating factor (filgrastim) 10 μg/kg per 
day subcutaneously, divided in two doses per day, from day 5 until last stem cell collection. 
After induction therapy, patients received one or two cycles of high-dose melphalan (200 mg/
m² intravenously) with autologous stem cell rescue followed by maintenance treatment with 
thalidomide (50 mg per day orally; group assigned to vincristine-based induction treatment) or 
bortezomib (1.3 mg/m² intravenously once every 2 weeks; group assigned to bortezomib-based 
induction treatment) for 2 years. Treatment was not masked for physicians and patients.
Severity of neuropathy was graded at baseline and after each treatment cycle by use of the 
National Cancer Institute’s Common Toxicity Criteria for Adverse Events criteria (version 3.0).18 All 
data were analyzed centrally. No neurological assessment was undertaken to objectify periph-
eral neuropathy. Since grade 1 peripheral neuropathy could easily be missed or misinterpreted, 
and because it does not include pain or interfere with the activities of daily life, we decided that 
grade 1 peripheral neuropathy was not clinically significant enough for the molecular analysis 
and therefore cases of this grade were excluded. Furthermore, the dose-modification guidelines 
established during the SUMMIT,6 CREST,5 and APEX19 trials did not recommend discontinuation 
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of bortezomib or dose modifications when grade 1 bortezomib induced peripheral neuropathy 
occurred. We did not routinely assess data for diabetes and vascular disease. Development of 
peripheral neuropathy after the first cycle of induction treatment is described as early onset, 
and after two to three cycles of induction treatment as late onset. Vincristine induced peripheral 
neuropathy was used as a reference when we assessed the incidence and severity of bortezomib 
induced peripheral neuropathy.
RNA isolation and microarray processing was done as previously described.20 Microarray data 
presented in this report have been stored in the Gene Expression Omnibus database (National 
Center for Biotechnology Information, Bethesda MD, USA), accession number GSE19784. Gene 
expression arrays were done with RNA extracted from myeloma plasma cells that were purified (≥ 
80%) from the extra bone marrow aspiration taken at diagnosis and met the criteria for quality.20
DNA was extracted from peripheral blood nucleated cells or CD138-negative bone marrow 
cells and quantified by use of the Nanodrop Spectrophotometer (Nanodrop, Wilmington, DE, 
USA). Samples were genotyped by use of the Affymetrix Targeted Genotyping (Affymetrix, Santa 
Clara, CA, USA) custom-built panel, with 3404 SNPs, selected with a hypothesis-driven strategy, 
targeting genes and SNPs for which associations or putative functional effects have been noted 
(Corthals SL, unpublished data). 
Statistical analysis
For differences in incidence of baseline and grade 2–4 peripheral neuropathy after one cycle 
and after two to three cycles of bortezomib-based and vincristine-based treatment, χ² analysis 
was done with a two-sided P value of 0.05. For gene expression data, class comparison of groups 
of arrays was done with one-way ANOVA in Partek Genomics Suite (version 6.4), followed by 
multiple test correction with a false discovery rate of less than 0.05. 
For SNP genotyping data, deviations from Fisher’s exact t test for Hardy-Weinberg equilib-
rium at P < 0.00001 and bias in missing data were controlled for each SNP. SNPs with a minor 
allele frequency of less than 5% and a call rate of less than 80% were removed from further 
analysis. To assess SNP associations with treatment related peripheral neuropathy and calcula-
tion of odds ratios (ORs), a Cochran-Armitage trend test and a Fisher’s t exact test were done. 
We assessed the genomic inflation factor λ based on the median χ² for each analysis with PLINK 
(version 1.07).21 To account for multiple testing, 10.000 permutation tests were done with the 
max(T) permutation procedure with PLINK. To assess the effect of nonsynonymous SNPs as-
sociated with bortezomib induced peripheral neuropathy and vincristine induced peripheral 
neuropathy, SNPs were characterized by use of the prediction program Sorting Intolerant From 
Tolerant (version 4.0.3).
Analysis of the gene and SNP sets for peripheral neuropathy associated with bortezomib and 
vincristine was done by use of Ingenuity Pathway Analysis software (version 8.7).
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This study is registered as an International Standard Randomized Controlled Trial, number 
ISRCTN64455289.
Role of the funding source
The sponsors had no role in the design, gathering, analysis, and interpretation of the data, or 
the writing of the report. The corresponding author had full access to all the data and the final 
responsibility to submit for publication.
 
Results
We did gene expression arrays for 329 (39%; 170 treated with bortezomib, 159 treated with 
vincristine) of 833 patients included in the trial, and SNP profiles for samples taken from 369 
(44%; 186 treated with bortezomib, 183 treated with vincristine) patients. Simultaneous gene 
expression and SNP data were obtained for 185 patients; only SNP data were available for 184 
patients, and only gene expression data were available for 144 patients. The baseline clinical 
characteristics of 513 patients included in this study were not different from the whole patient 
group included in the trial (Table S1). 
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Table 1.  Incidence of baseline, bortezomib induced, and vincristine induced peripheral neuropathy.
Bortezomib-based induction Vincristine-based induction
treatment (n = 250) treatment (n = 250) P-value
Baseline peripheral neuropathy 8 (3%) 13 (5%) 0.37
Peripheral neuropathy after one cycle
PNP grade 2 - 4 20 (8%) 11 (4%) 0.27
PNP grade 2 10 (50%) 9 (82%)
PNP grade 3 7 (35%) 1 (9%) 0.18*
PNP grade 4 3 (15%) 1 (9%)
Peripheral neuropathy after two or three cycles
PNP grade 2 - 4 66 (26%) 17 (7%) < 0.0001
PNP grade 2 31 (47%) 11 (65%)
PNP grade 3 24 (36%) 6 (35%) 0.72*
PNP grade 4 8 (12%) 0 (0%)
Data are number (%), unless otherwise indicated. The denominator for calculation of the percentages of 
patients with grades 2, 3, and 4 drug related peripheral neuropathy was the total number of patients present-
ing with drug related peripheral neuropathy after one or two to three cycles of treatment, respectively. *For 
difference in percentage of patients with grade 3 and 4 peripheral neuropathy associated with bortezomib 
and vincristine among the total number of patients presenting with grade 2–4 bortezomib induced and 
vincristine induced peripheral neuropathy, respectively.
Table 1 shows the incidence of peripheral neuropathy at baseline and after treatment with 
bortezomib-based and vincristine-based induction treatments in 500 of 513 patients who were 
fully assessable and had a minimum follow-up of 40 months. The median time to development 
of bortezomib induced peripheral neuro pathy was 42 days (range 0–137). Cumulative dose of 
bortezomib given before development of peripheral neuropathy was 13 mg/m². 52 patients 
(21%) developed grade 1 bortezomib induced peripheral neuropathy, and 34 (14%) developed 
grade 1 peripheral neuropathy before progressing to a higher grade. When patients developed 
peripheral neuropathy, the dose of bortezomib was adjusted according to the established guide-
lines for dose modification.5–7,19 Median time to development of vincristine induced peripheral 
neuropathy was 37 days (range 0–171). Cumulative dose of vincristine given before development 
of peripheral neuropathy was 4 mg. 60 (24%) patients developed vincristine induced periph-
eral neuropathy, and 18 (7%) developed grade 1 peripheral neuropathy before progressing to 
a higher grade. When patients developed vincristine induced peripheral neuropathy, vincristine 
was discontinued and supportive treatments such as pregabalin were used. Overall, baseline 
peripheral neuropathy was noted in only a small number of patients (Table 1). The proportion 
of patients developing late onset bortezomib induced peripheral neuropathy was significantly 
higher than that of patients with late onset vincristine induced peripheral neuropathy (Table 1).
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Table 2. Differentially expressed genes in early onset and late onset bortezomib induced and vincristine 
induced peripheral neuropathy.
Probeset ID Gene name Gene description Factor 
difference in 
expression
P-value
Grade 2-4 peripheral neuropathy (n=15) versus no peripheral neuropathy (n=134) after one cycle of bortezomib
225189_s_at RAPH1 Ras association (RalGDS/AF-6) and pleckstrin homology domains 1 2.24 3.04 x 10-2
235014_at LOC147727 Hypothetical LOC147727 2.15 1.91 x 10-2
1569872_a_at LOC650392 Hypothetical protein LOC650392 1.98 9.65 x 10-4
213056_at FRMD4B FERM domain containing 4B 1.74 8.42 x 10-3
227984_at LOC650392 Hypothetical protein LOC650392 1.71 1.19 x 10-3
225478_at MFHAS1 Malignant fibrous histiocytoma amplified sequence 1 1.68 5.34 x 10-9
226913_s_at SOX8 SRY (sex determining region Y)-box 8 1.68 4.28 x 10-13
204810_s_at CKM Creatine kinase, muscle 1.67 1.11 x 10-30
1569871_at LOC650392 Hypothetical protein LOC650392 1.65 1.77 x 10-19
228057_at DDIT4L DNA-damage-inducible transcript 4-like 1.59 5.59 x 10-20
Grade 2-4 peripheral neuropathy (n=44) versus no peripheral neuropathy (n=78) after two or three cycles of bortezomib
205590_at RASGRP1 RAS guanyl releasing protein 1 (calcium and DAG-regulated) 2.97 2.14 x 10-2
204527_at MYO5A Myosin VA (heavy chain 12, myoxin) 1.93 3.21 x 10-2
235065_at ... ... 1.57 3.19 x 10-2
205422_s_at ITGBL1 Integrin, beta-like 1 (with EGF-like repeat domains) 1.44 1.35 x 10-3
228113_at RAB37 RAB37, member RAS oncogene family 1.41 3.69 x 10-3
210321_at GZMH Granzyme H (cathepsin G-like 2, protein h-CCPX) 1.37 3.19 x 10-2
226969_at MTR 5-methyltetrahydrofolate-homocysteine methyltransferase 1.34 4.26 x 10-2
204072_s_at FRY Furry homolog (Drosophila) 1.31 4.94 x 10-2
236442_at DPF3 D4, zinc and double PHD fingers, family 3 1.30 3.38 x 10-3
243329_at ... ... 1.30 4.26 x 10-2
Grade 2-4 peripheral neuropathy (n=9) versus no peripheral neuropathy (n=129) after one cycle of vincristine
208235_x_at GAGE7 G antigen 7 11.55 3.21 x 10-3
206640_x_at GAGE12I G antigen 12I 11.46 4.29 x 10-3
207739_s_at GAGE2C G antigen 2C 7.76 1.62 x 10-3
208155_x_at GAGE6 G antigen 6 6.88 1.06 x 10-5
206897_at PAGE1 P antigen family, member 1 (prostate associated) 6.76 4.29 x 10-3
216063_at HBBP1 Hemoglobin, beta pseudogene 1 6.24 4.04 x 10-2
207086_x_at GAGE4 G antigen 4 6.16 3.29 x 10-5
206626_x_at SSX1 Synovial sarcoma, X breakpoint 1 5.93 2.61 x 10-2
207912_s_at DAZ1 Deleted in azoospermia 1 5.86 1.06 x 10-4
214957_at ACTL8 Actin-like 8 4.93 1.32 x 10-10
Grade 2-4 peripheral neuropathy (n=10) versus no peripheral neuropathy (n=103) after two or three cycles of vincristine
210632_s_at SGCA Sarcoglycan, alpha (50kDa dystrophin-associated glycoprotein) 4.08 3.35 x 10-2
210992_x_at FCGR2C Fc fragment of IgG, low affinity IIc, receptor for (CD32) 2.49 3.57 x 10-2
241991_at ... ... 1.80 3.35 x 10-2
206771_at UPK3A Uroplakin 3A 1.59 2.94 x 10-2
241365_at ... ... 1.57 3.35 x 10-2
236266_at RORA RAR-related orphan receptor A 1.53 2.94 x 10-2
214059_at IFI44 Interferon-induced protein 44 1.51 4.92 x 10-6
230477_at ... ... 1.48 2.94 x 10-2
237322_at MIAT Myocardial infarction associated transcript (non-protein coding) 1.45 2.94 x 10-2
239239_at ... ... 1.33 2.94 x 10-2
First column is the probe set identification number. Genes were ranked from highest to lowest change; the 
first ten genes with the highest changes are shown.
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Gene expression arrays for 15 patients developing early onset grade 2–4 bortezomib induced 
peripheral neuropathy were compared with arrays of patients who did not develop bortezomib 
induced peripheral neuropathy (Table 2). Grade 2–4 early onset bortezomib induced peripheral 
neuropathy was characterized by 19 differentially expressed genes (false discovery rate < 0.05). 
The genes showing the highest changes in the gene expression arrays are shown in Table 2, and 
the complete number of differentially expressed probe sets are shown in Table S2. The genes 
showing the highest change in expression included RAPH1 (involved in signal transduction), FR-
MD4B, MFHAS1 (possibly an oncogene regulated by NFκB or tumor necrosis factor), and DDIT4L 
(a DNA-damage inducible transcript; Table 2). Genes that might play a direct part in bortezomib 
induced peripheral neuropathy are transcription regulator SOX8 (involved in development of 
peripheral nervous system), CPT1C and RHOBTB2 (Table S2). Ingenuity pathway analyses of gene 
and SNP sets showed enrichment of genes implicated in the canonical pathway of signaling 
mediated by AMP-activated protein kinase (AMPK), including CPT1C, CKM, and PIK3CG (three of 
156 genes involved in AMPK signaling were upregulated, P = 7.33 x 10 -⁵).
Gene expression arrays for 44 patients with grade 2–4 late onset bortezomib induced periph-
eral neuropathy were characterized by 27 differentially expressed genes, using the same false 
discovery rate as for early onset (Table S2), and showed a different pattern of gene expression 
to that in early onset bortezomib induced peripheral neuro pathy, without overlap (Table 2). 
RASGRP1 showed the highest change in patients with late onset bortezomib induced peripheral 
neuropathy compared with patients without this side effect (Table 2). Furthermore, we noted 
upregulation of genes involved in transcription regulation, including TRERF1, TRPS1, and MDM2. 
We noted enrichment of genes involved in the development and function of the nervous system, 
including SOD2 and MYO5A. 
All significant SNPs (permuted P < 0.01) associated with grade 2–4 early onset bortezomib 
induced peripheral neuropathy are shown in Table 3 (values of permuted P < 0.05 are shown 
in Table S3). Several SNPs associated with early onset bortezomib induced peri pheral neuropa-
thy were located in caspase 9 (rs4646091, rs2020895, rs2020903, rs4646032, and rs4646034). 
Other highly associated SNPs were located in genes RDM1, ALOX12, IGF1R, and LSM1 (Table 3). 
Pathway analysis of these associated genes showed enrichment of genes involved in cell death 
(14 genes, P = 5.25 x 10-³–4.93 x 10-²), DNA repair (14 genes, P = 5.25 x 10-³–4.93 x 10-²), and 
development and function of the nervous system (four genes, P = 2.01 x 10-³).
The SNPs that were characteristic of late onset bortezomib induced peripheral neuropathy 
were mainly located in DNA repair genes, such as ERCC3, ERCC4, ATM, BRCA1, EXO1, and MRE11A 
(Table 3, and S3). Pathway analysis showed enrichment of associated SNPs located in genes in-
volved in the development and function of the nervous system (three genes, P = 3.35 x 10-³–1.69 
x 10-²) and in inflammatory disease (26 genes, P = 2.09 x 10-³–4.95 x 10-³). 
The genetic profile of myeloma plasma cells from nine patients who developed grade 2–4 
early onset vincristine induced peripheral neuropathy showed overexpression of the genes for 
testis cancer antigens, of which the GAGE genes were mainly upregulated (Table 2). 
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Table 3. Single nucleotide polymorphisms associated with bortezomib induced and vincristine induced 
peripheral neuropathy.
SNP ID Chromosome Gene Single nucleotide polymorphism type Odds ratio (95% CI) P-value Permuted P-value
Grade 2–4 peripheral neuropathy (n=13) versus no peripheral neuropathy (n=147) after one cycle of bortezomib
rs2251660 17 RDM1 Coding-nonsynonymous 3.65 (1.55-8.57) 9.06 x10-4 2.40 x10-3
rs4646091 1 CASP9 Intron 3.56 (1.59-8.14) 1.43 x10-3 2.90 x10-3
rs1126667 17 ALOX12 Coding-nonsynonymous 3.50 (1.47-8.32) 2.95 x10-3 3.80 x10-3
rs434473 17 ALOX12 Coding-nonsynonymous 3.50 (1.47-8.32) 2.95 x10-3 4.10 x10-3
rs7823144 8 LSM1 Intron 4.11 (1.48-11.39) 2.30 x10-3 7.60 x10-3
rs1879612 15 IGF1R Intron 0.22 (0.07-0.77) 9.42 x10-3 8.30 x10-3
rs1029871 3 NEK4 Coding-nonsynonymous 0.30 (0.11-0.81) 8.31 x10-3 9.30 x10-3
Grade 2–4 peripheral neuropathy versus (n=49) no peripheral neuropathy (n=80) after two or three cycles of bortezomib
rs1799800 16 ERCC4 Intron 2.74 (1.56-4.84) 5.16 x10-4 1.00 x10-3
rs1799801 16 ERCC4 Coding-synonymous 2.48 (1.43-4.28) 8.85 x10-4 1.10 x10-3
rs2300697 2 SRD5A2 Intron 0.63 (0.37-1.05) 4.80 x10-2 2.90 x10-3
rs1059293 21 IFNGR2 Untranslated,Intron 2.30 (1.37-3.87) 8.97 x10-4 3.20 x10-3
rs2276583 2 ERCC3 Locus 1.26 (0.75-2.12) 3.87 x10-1 3.30 x10-3
rs189037 11 ATM Locus,Untranslated 0.53 (0.32-0.89) 2.32 x10-2 3.60 x10-3
rs10501815 11 MRE11A Intron,TagSNP:MRE11A 3.27 (1.39-7.74) 4.41 x10-3 4.20 x10-3
rs664677 11 ATM Intron 0.57 (0.34-0.96) 4.36 x10-2 5.90 x10-3
rs664982 11 ATM Intron 0.51 (0.30-0.85) 1.72 x10-2 6.20 x10-3
rs6131 1 SELP Coding-nonsynonymous 0.43 (0.23-0.83) 6.69 x10-3 6.30 x10-3
rs1130499 7 PTPRN2 Coding-nonsynonymous 0.43 (0.23-0.79) 6.23 x10-3 6.60 x10-3
rs4722266 7 STK31 Coding-nonsynonymous 0.29 (0.12-0.74) 5.66 x10-3 8.30 x10-3
rs2267668 6 PPARD Intron 0.35 (0.15-0.83) 9.30 x10-3 9.10 x10-3
Grade 2–4 peripheral neuropathy versus (n=7) no peripheral neuropathy (n=151) after one cycle of vincristine
rs7739752 6 PPARD Intron 13.43 (3.90-46.22) 6.34 x10-7 8.00 x10-4
rs2288087 9 ALDH1A1 Intron,TagSNP:ALDH1A1 7.62 (1.68-34.65) 1.40 x10-3 1.50 x10-3
rs1494961 4 HEL308 Coding-nonsynonymous 6.67 (1.47-30.32) 2.30 x10-3 2.60 x10-3
rs6901410 6 PPARD Intron 9.67 (2.65-35.30) 7.75 x10-5 6.00 x10-3
rs6902123 6 PPARD Intron 9.67 (2.65-35.30) 7.75 x10-5 6.00 x10-3
rs2274407 13 ABCC4 Coding-nonsynonymous 7.15 (2.02-25.31) 2.94 x10-4 6.10 x10-3
rs909253 6 LTA Intron 4.67 (1.52-14.34) 3.09 x10-3 6.60 x10-3
rs6457816 6 PPARD Intron 8.89 (2.46-32.17) 1.40 x10-4 7.30 x10-3
rs1041981 6 LTA Coding-nonsynonymous 4.52 (1.47-13.88) 3.58 x10-3 7.40 x10-3
rs3803258 13 SLC10A2 Untranslated 4.30 (1.45-12.74) 3.51 x10-3 7.40 x10-3
rs3749442 3 ABCC5 Coding-synonymous 4.64 (1.53-14.05) 2.72 x10-3 9.60 x10-3
Grade 2–3 peripheral neuropathy (n=14) versus no peripheral neuropathy (n=104) after two or three cycles of vincristine
rs10515114 5 CART Locus 4.62 (1.68-12.72) 7.92 x10-4 2.90 x10-3
rs6873545 5 GHR Intron 0.09 (0.01-0.67) 3.44 x10-3 3.60 x10-3
rs3734354 6 SIM1 Coding-nonsynonymous 3.30 (1.39-7.82) 2.31 x10-3 5.10 x10-3
rs11688 1 JUN Coding-synonymous 5.00 (1.8-13.91) 9.10 x10-4 5.20 x10-3
rs4129472 5 GHR Intron 0.11 (0.01-0.80) 6.46 x10-3 5.20 x10-3
rs1413239 1 DPYD Intron,TagSNP:DPYD 3.29 (1.47-7.37) 3.03 x10-3 5.40 x10-3
rs1045020 5 SLC22A5 Untranslated 4.80 (1.83-12.61) 1.48 x10-3 5.40 x10-3
rs9885672 6 KIAA0274 Coding-nonsynonymous 3.89 (1.62-9.33) 2.05 x10-3 5.60 x10-3
rs3887412 16 ABCC1 Intron,TagSNP:ABCC1 3.36 (1.47-7.67) 3.31 x10-3 5.70 x10-3
rs6886047 5 GHR Intron 0.10 (0.01-0.72) 3.97 x10-3 6.10 x10-3
rs1236913 9 PTGS1 Coding-nonsynonymous 5.40 (1.79-16.28) 1.43 x10-3 6.30 x10-3
rs2644983 16 ABCC1 Intron,TagSNP:ABCC1 4.22 (1.69-10.50) 2.27 x10-3 6.60 x10-3
rs1042713 5 ADRB2 Coding-nonsynonymous 0.23 (0.08-0.69) 5.30 x10-3 7.20 x10-3
rs1966265 5 FGFR4 Coding-nonsynonymous 3.47 (1.51-7.94) 3.40 x10-3 7.30 x10-3
rs2308327 10 MGMT Coding-nonsynonymous 3.38 (1.33-8.58) 3.69 x10-3 7.30 x10-3
rs5759197 22 BZRP Intron 2.93 (1.31-6.53) 6.32 x10-3 7.60 x10-3
rs1005658 22 BZRP Locus 3.14 (1.39-7.08) 6.04 x10-3 8.50 x10-3
rs7441774 4 UGT2B7 Intron 3.60 (1.40-9.23) 6.61 x10-3 9.60 x10-3
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The gene profiles of ten patients who developed grade 2 or 3 late onset vincristine induced 
peripheral neuro pathy showed only ten differentially expressed genes, including RORA and IFI44 
(Table 2).
Table 3 shows SNPs significantly associated with early onset vincristine induced periph-
eral neuropathy. Four of the most highly associated SNPs (rs7739752, rs6901410, rs6902123, and 
rs6457816) were located in the transcription factor PPARD. Additionally, an intronic (rs909253) 
and a coding nonsynonymous SNP (rs1041981) in LTA were significantly associated with early 
onset vincristine induced peripheral neuropathy. Other significant SNPs were located in genes 
for transporter enzymes ABCC4, ABCC5, and SLC10A2, oxidizing enzyme ALDH1A1, and GLI1 (Table 
3 and S3). Pathway analysis showed enrichment of associated SNPs located in genes involved in 
cellular growth and proliferation (four genes, P = 1.14 x 10-²–4.95 x 10-²).
Some intronic SNPs in the dihydropyrimidine dehydrogenase gene DPYD and some in the 
ABC transporter gene ABCC1 were associated with late onset vincristine induced peripheral 
neuropathy (Table 3). Pathway analysis showed that most significant SNPs (permuted P < 0.05) 
were located in genes for absorption, distribution, metabolism, and excretion (six genes, P = 2.06 
x 10-²–4.18 x 10-²).
 
Discussion
The genetic profiles of patients with early onset bortezomib induced peripheral neuropathy sug-
gest the involvement of genes involved in transcription, apoptosis, and AMPK-mediated signal-
ing. The possible role of AMPK-mediated signaling is of particular interest because this enzyme 
functions by stimulating the signaling pathways that replenish cellular ATP supplies in response 
to low glucose, hypoxia, ischaemia, or heat shock, which might be triggered in myeloma cells 
in response to bortezomib. CPT1C codes for an enzyme found in neuron mitochondria that is 
involved in transport of hydrophobic fatty acid chains into mitochondria, and plays a part in mi-
tochondrial dysfunction. It might also have an important role in bortezomib induced peripheral 
neuropathy, since damage to mitochondria and endoplasmic reticulum through activation of a 
mitochondrial-based apoptotic pathway by bortezomib was noted in dorsal root ganglia of mice 
given bortezomib.11 RHOBTB2, encodes another enzyme implicated here, has been shown to be 
upregulated during drug induced apoptosis, being mainly dependent on E2F1.22 Knockout of 
RHOBTB2 with small interfering RNAs has been shown to delay the onset of drug induced apop-
tosis.22 RASGRP1 is involved in many processes, including apoptosis and calcium-ion binding, 
which are potentially interesting for its role in bortezomib induced peripheral neuropathy. The 
presence of polymorphisms in the apoptosis gene caspase 9, which plays an important part in 
bortezomib induced apoptosis, suggests the possible contribution of this enzyme to early onset 
peripheral neuropathy.23,24 One of the most significant SNPs (rs1029871) might have a role in 
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the splicing regulation of NEK4, which is involved in the regulation of cell cycle and cell division. 
Furthermore, SNPs in enriched pathways like DNA repair and nervous system development and 
function were associated with early onset bortezomib induced peripheral neuropathy.
Late onset bortezomib induced peripheral neuropathy was associated with genes involved in 
the development and function of the nervous system. We noted upregulation of the superoxide 
dismutase gene SOD2 in myeloma plasma cells; SOD2 is regulated by tumor necrosis factor α 
and NFκB, and is known to have a role in the survival of neurons. Patients with diabetes and a 
polymorphism in the SOD2 gene, leading to reduced SOD2 activity, have been shown to be at in-
creased risk of developing diabetic peripheral neuropathy.25 The protective effect of SOD2 might 
be eliminated with bortezomib induced apoptosis, which might trigger a susceptibility to oxida-
tive stress in treated patients. Three SNPs associated with late onset bortezomib induced periph-
eral neuropathy were located in SERPINB2 (plasminogen activator inhibitor-2). SERPINB2, with 
SERPIN-1 (plasminogen activator inhibitor-1), tissue-type plasminogen activator, and urokinase-
type plasminogen activator, has been shown to be induced in dorsal root ganglion neurons after 
peripheral axotomy in mice.26 These serpins might also act as autocrine or paracrine regulators 
of plasminogen-activator-mediated nerve regeneration processes.26 The associated SNPs might 
affect SERPINB2 expression through their effect on splicing regulation. Besides genes involved in 
development of the nervous system, proinflammatory genes might play an important part in the 
pathogenesis of late onset bortezomib induced peripheral neuropathy, based on the presence 
of intronic SNPs in MBL2 and PPARD (Corthals SL, unpublished data), and of about 30% of SNPs 
with reported inflammatory roles. The hypothesis that the DNA repair pathway is involved in 
bortezomib induced peripheral neuropathy, and that this side effect might be caused by the 
inability to repair neuronal damage (Corthals SL, unpublished data), could be substantiated by 
the presence of SNPs in BRCA1 (rs16941 and rs799917). These nonsynonymous SNPs might have 
an effect on the phosphorylation state of a protein, which has been shown to abolish the P871L 
phosphorylation site in BRCA1.27 Therefore, early onset and late onset bortezomib induced pe-
ripheral neuropathies were both associated with a myeloma genetic profile that was character-
ized by genes involved in the development of the nervous system; however, apoptosis was also 
a characteristic for the development of early onset bortezomib induced peripheral neuropathy. 
Genetic polymorphisms in genes involved in nervous system development and DNA repair play 
a part in both the early and late onset of this side effect.
A comparison of the molecular profiles of bortezomib induced peripheral neuropathy and 
vincristine induced peripheral neuropathy showed no overlap in associated genes or SNPs. 
Genes involved in cell cycle and proliferation were mainly associated with early onset vincristine 
induced peripheral neuropathy, both in the analyses of genetic pathways and SNPs. Additionally, 
involvement of proinflammatory genes in early onset vincristine induced peripheral neuropathy 
was substantiated by the finding of SNPs in PARP1 and LTA, and two SNPs in GLI1 (rs2228224 and 
rs2228226), which both encode an amino acid change; rs2228226 has been shown to affect GLI1 
activity, thereby affecting the inflammatory response.28
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Genes implicated in drug absorption, distribution, metabolism, and excretion have been 
shown to be involved in chemotherapy induced peripheral neuro pathy.29 In accordance with 
this finding, an association was noted for late onset vincristine induced peripheral neuropathy 
with nine intronic SNPs in ABCC1; vincristine is known to be a substrate of the protein coded for 
by this gene. 
In conclusion, this study provides the first large dataset in which the contribution of both the 
inherited genetic constitution of the host (patient) and the tumor (myeloma) to the development 
of bortezomib induced peripheral neuropathy has been reported (panel). We identified molecu-
lar factors that are associated with bortezomib induced peripheral neuropathy in patients with 
newly diagnosed multiple myeloma. Genes for apoptosis contribute to early onset bortezomib 
induced peripheral neuropathy, whereas genes that have a role in inflammatory pathways and 
DNA repair contribute to the development of late onset peripheral neuropathy, indicating that 
distinct genetic factors are involved in the development of early onset and late onset forms of this 
side effect. Bortezomib induced and vincristine induced peripheral neuropathy arise through dif-
ferent molecular mechanisms. Our findings strongly suggest an interaction between myeloma 
related factors and the patient’s genetic background in the development of bortezomib induced 
peripheral neuropathy. Profiles of genetic risk might be used in future to identify patients with 
an increased risk of bortezomib induced peripheral neuropathy.
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Abstract
Deletion of chromosome 13, observed in more than 50% of multiple myeloma (MM) patients, is 
associated with poor prognosis; however, a tumor suppressor gene has not yet been identified in 
the region. We have investigated whether miRNA-15a and miRNA-16-1, located on chromosome 
13q14, are downregulated or deleted in 26 MM patients.
Deletions of chromosome 13 were observed in 12/26 (46.2%) MM patients when analyzed by 
FISH. Copy number variation (CNV) analysis with SNP mapping arrays have defined 8 additional 
patients with a chromosome 13 aberration at the miRNA-15a and miRNA-16-1 location. Overall, 
chromosome 13q14.3 deletions were present in 20/26 (76.9%) of MM patients. Both miRNAs 
displayed a wide range of expression, while no difference in miRNA-15a or miRNA-16 expression 
between patients with or without a chromosome 13 deletion was found.
MiRNA-15a and miRNA-16 display a range of expression patterns in MM patients, independent 
of the chromosome 13 status. These findings suggest that genes other than miRNA-15a and 
miRNA-16 may be involved in the mechanism underlying the prognostic significance of chromo-
some 13q deletions. Furthermore, the results show that CNV analysis using SNP mapping arrays 
is a more comprehensive and accurate method to determine chromosome 13 aberrations than 
standard FISH.
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Introduction
Multiple myeloma (MM) is a plasma cell malignancy, characterized by the accumulation of malig-
nant plasma cells in the bone marrow (BM). MM represents approximately 15% of all hematologi-
cal malignancies.1 In spite of conventional and high-dose chemotherapy treatment followed by 
stem cell transplantation, all patients eventually relapse and their median survival is 3-5 years.2
MM is characterized by profound genetic instability, leading to chromosomal abnormalities. 
Chromosomal translocations are early events in disease progression and seem to play an im-
portant role in the genetic pathogenesis of MM. The most common abnormality observed is a 
deletion of chromosome 13, which is seen in more than 50% of MM cases and is an early event in 
MM pathogenesis. Such aberrations of chromosome 13, are detectable in all stages of myeloma 
and normally involve large segments or the entire long arm, however small interstitial deletions 
have also been described.3 The most commonly deleted marker in the 13q14 region is D13S319,4 
located distal to the retinoblastoma-1 (RB1) gene. Since deletions at chromosome 13 have been 
associated with poor prognosis,5-11 it is now common practice to determine the presence of 
chromosome 13 deletions by fluorescence in situ hybridization (FISH) in patients with newly 
diagnosed MM. Because of the adverse prognostic role of these deletions, the presence of MM 
tumor suppressor gene(s) on chromosome 13q has been suggested, but so far not identified. 
MicroRNAs (miRNAs) are a class of small non-coding single stranded RNAs of approximately 22 
nucleotides in length. So far, more than 500 human miRNAs have been reported in literature.12 
MiRNAs negatively regulate gene expression by binding to partially complementary sites in 
messenger RNAs (mRNAs). As a result, the mRNA is degraded or remains untranslated, leading to 
decreased levels of mRNA and protein respectively.13 
A large number of miRNAs are located at fragile sites across the human genome. These sites are 
often deleted or amplified at a common breakpoint, and they are frequently associated with can-
cer.14 Therefore, miRNAs have been suggested to function as tumor suppressor and oncogenes 
and play a role in the pathogenesis of MM.15 In chronic lymphocytic leukemia (CLL), miRNA-15a 
and miRNA-16-1; located on chromosome 13q14, are frequently downregulated or deleted and 
therefore a tumor suppressor activity and pathogenic role has been hypothesized.16-17 
The aim of this study is to evaluate the expression of miRNA-15a and miRNA-16 in MM and to 
study the potential association between miRNA expression levels and chromosome 13 deletions 
in myeloma plasma cells.
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Materials and methods
Patient samples and cell lines
We obtained bone marrow samples from newly diagnosed patients with MM who were included 
in a prospective randomized clinical trial. Bone marrow aspirates were obtained from the poste-
rior iliac crest and bone marrow cells were freshly separated by density gradient centrifugation 
over Histopaque 1077 (Sigma-Aldrich, St. Louis, MO). Myeloma plasma cells were then purified 
using CD138 magnetic microbeads (MACS system, Miltenyi Biotec, Bergisch Gladbach, Germany). 
Enriched aliquots were assessed for purity and samples with CD138 positive plasma cell purity > 
80% were included in this study. 
RNA isolation
Small RNAs; transcripts less than 200 nucleotides in length including miRNAs, were isolated 
from CD138 magnetic cell selected (MACS) MM plasma cells using miRVana miRNA Isolation Kit 
(Ambion, Austin, TX, USA), according to manufacturer´s protocol. 
RNA levels and quality were assessed using the Agilent 2100 Bioanalyzer (Agilent Technolo-
gies).
PCR analysis
Mature miRNA-15a and miRNA-16 expression levels in MM plasma cells were determined by real-
time PCR using TaqMan miRNA assay; which uses stem-loop reverse transcription (RT) followed 
by real-time PCR (Applied Biosystems, P/N: 4373123 and 4373121).18 Briefly, 10 ng of small RNA 
was used in each 15 µl reaction, and reverse transcribed to cDNA. RT reactions were carried out at 
16 °C for 30 min; 42 °C for 30 min; 85 °C for 5 min and then held at 4 °C. All RT reactions including 
no-template controls were run in duplicate.
Next, 1.33 µl of this RT product was used for a 20 µl real-time PCR reaction, containing 10 µl 
TaqMan 2x Universal PCR Master Mix, No AmpErase uracil-N-glycosylase (Applied Biosystems), 
1 µl TaqMan MicroRNA assay 20x, and 7.67 µl nuclease free water. The reaction mixture was 
incubated at 95 °C for 10 min, followed by 40 amplification cycles of 95 °C for 15 sec and 60 °C 
for 1 min by using the ABI 7900 HT Sequence Detection System (SDS; Applied Biosystems). The 
threshold cycle (Ct) is defined as the fractional cycle number at which the fluorescence passes 
the fixed threshold. All experiments were performed in duplicate and miRNAs were considered 
as present when Ct-values were lower than 35.
SNP mapping array analysis
Genomic DNA was isolated from peripheral blood by salting out precipitation. Tumor DNA was 
extracted from CD138 MACS MM plasma cells using Qiagen RNAeasy kit (Qiagen, Valencia, CA) 
according to the manufacturer’s protocol. Genome-wide single nucleotide polymorphism (SNP) 
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genotyping was performed using the Illumina Infinium HumanHap550 Genotyping BeadChip 
according to manufacturer’s instructions (Illumina, San Diego, CA, USA) containing over 550.000 
unique tag SNP markers. 
Genotypes for all arrays were calculated using BeadStudio’s genotyping module (v2.0, Illu-
mina). Data was imported into Partek Genomics Suite 6.4 software (Partek Inc., St Louis, MO) 
for further analysis; allele intensities were calculated for 25 genomic DNA MM samples and 26 
tumor DNA MM samples, of which 20 had paired normal samples. For these 20 samples, paired 
analysis was performed. For the remaining 6 samples, a group of 25 genomic blood DNA MM 
samples was set as a baseline for calculating genotypes and DNA copy number (CN). The CN at 
each SNP was estimated from the allele intensity data by normalizing each sample to a reference 
(paired or baseline). In addition, allele specific copy number variation (AsCN) was calculated by 
estimating the number of copies for each allele, rather than total copies of each chromosome. 
Significant regions of aberration for each sample were found by the segmentation algorithm 
according to the following criteria: 1) neighboring regions have statistically significantly differ-
ent mean intensities (P < 0.0001), 2) minimum signal to noise ratio for each transition of 0.3, 3) 
breakpoints (region boundaries) were chosen to give optimal statistical significance (P < 0.0001), 
4) detected regions must contain a minimum of 10 markers. Finally, loss of heterozygosity (LOH) 
was estimated from the imported sample genotypes (Beadstudio) by a Hidden Markov Model, 
using the same baseline as in the segmentation algorithm (25 genomic blood DNA MM samples). 
CN, AsCN, LOH and allelic ratios were integrated and visualized in a genomic browser within 
Partek Genomics Suite.
Cytogenetic analysis and FISH
Chromosome analysis was performed on fresh bone marrow samples taken at diagnosis. These 
samples were cultured in RPMI medium with 10% serum and in Iscove’s medium containing 
interleukin 4 and interleukin 6, and harvested after 96 hours according to standard cytogenetic 
techniques. Metaphase cells were analyzed using both QFQ- and RBA-banding. The resulting 
karyotypes were described according to the International System for Human Cytogenetic No-
menclature.19
Fluorescence in situ hybridization (FISH) was performed using standard protocols.20 LSI 
D13S319 (13q14.3) SpectrumOrange Probe was used to detect 13q14 deletions in combination 
with CEP 9 SpectrumGreen Probe to detect additional copies of chromosome 9 indicative for the 
presence of a hyperdiploid clone (Vysis, Abbott Molecular, Abbott Park, Illinois, USA).  In addition, 
LSI 13 (RB1) 13q14 SpectrumOrange Probe was used to determine the deletion status of the RB 
gene.
At least 200 interphase nuclei per sample were analyzed using an epi-fluorescence microscope 
(Zeiss, Axio-Imager Z1, Sliedrecht, The Netherlands) and Isis Software (Metasystems, Altlussheim, 
Germany), with a subsequent analysis of selected myeloma cells based on morphology. 
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Data analysis
SDS 2.3 software (Applied Biosystems) was used to analyze real-time RT-PCR data.
Accurate normalization of this data is essential for quantification of miRNA levels. In this study, 
the stability of five candidate reference small nuclear RNAs was examined using the validation 
program GeNorm.21 The two most stable reference genes, RNU24 (Applied Biosystems, P/N: 
4373379) and RNU48 (Applied Biosystems, P/N: 4373383), were selected and used for internal 
normalization. The relative expression levels of miRNA-15a and miRNA-16 compared to CD138 
sorted plasma cells from normal bone marrow were determined using the 2-DDCt method.22 
The Mann-Whitney U test was applied to determine if the presence of a chromosome 13 aber-
ration resulted in a significant difference of the miRNA-15a or miRNA-16 gene expression levels. 
These statistical analyses were performed with SPSS Statistical software version 11.0 for Win-
dows (SPSS Inc., Chicago, IL, USA). All analyses were two-tailed and differences were considered 
statistically significant when P-values were less than 0.05.
Results
Chromosome 13 deletions
We determined the chromosome 13 status of 26 MM patients by two different methods. Firstly, 
FISH analysis was performed showing chromosome 13 deletions in 11/26 patients (Table 1 and 
S1). However, with FISH analysis only the status of both probes RB1 and D13S319 located at 
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chromosome 13q14 are determined, while the exact locations of miRNA-15a and miRNA-16-1 
cannot be visualized. The presence of both probes does not exclude that miRNA-15a and 
miRNA-16-1 are absent by partial deletion. Using karyotyping, 1 additional patient (patient MM 
1) had a chromosome 13 deletion, resulting in 12/26 patients (46.2%) having a chromosome 13 
aberration detected. Secondly, we have performed copy number variation (CNV) analysis using 
SNP mapping arrays (Illumina Infinium HumanHap550 Genotyping BeadChip) to determine the 
exact deleted regions at chromosome 13. Paired analysis of purified MM cells with genomic DNA 
could be performed on 20/26 samples to determine CNV, while unpaired analysis was performed 
on 6/26 samples using the total group of genomic DNA samples as a baseline reference. The 
median genotype call rate in the 26 tumor samples was 93.7% (range: 83.6% - 99.3%) and in the 
25 control samples 99.6% (range: 94.7% - 99.9%).
Applying a segmentation algorithm on copy numbers, a minimally deleted region on chromo-
some 13 (49431816 bp – 49631113 bp), in which miRNA-15a and miRNA-16-1 are located, was 
observed in 20/26 patients, 15 of which were from the paired analysis (P < 0.00001; Table 1, 2, 
S1, S2, Figure 1, and S1). Segmentation analysis revealed 8 additional patients with a chromo-
some 13 deletion compared to FISH analysis. Deleted regions were determined with a minimum 
of 10 significant markers, however with 1 marker, negative samples remained negative. AsCN 
analysis further revealed the absence of homozygous deletions in these patients. Uniparental 
disomy (UPD; copy number-neutral LOH), was detected in one patient (MM 17) in small regions 
across chromosome 13, however at the exact location of miRNA-15a and miRNA-16-1 no UPD was 
detected in any patients (Figure 1 and Figure S1). 
We next examined the expression of transcripts other than miRNA-15a and miRNA-16-1, which 
are located within this deleted region. Known genes (NCBI) such as; ARL11, C13orf1, DLEU1, EBPL, 
KCNRG, KNAP3, PHF11, RCBTB1, SETDB2 and TRIM13, were located in this region, however, none 
of these genes are thought to be involved in the pathogenesis of MM (Table 1 and S1). In ac-
cordance with previous research, we did not find any changes in the expression of these genes 
for patients with a chromosome 13 deletion.
A highly correlated cluster of miRNAs; miRNA-15b and miRNA-16-2, is located on chromosome 
3. MiRNA-15a and miRNA-15b are derived from the same seed sequence, however they differ 
in their mature sequence. MiRNA-16-1 and miRNA-16-2 on the other hand do not differ in their 
mature sequence, and therefore cannot be distinguished. For this reason, we are not able to 
separate miRNA-16-1 and miRNA-16-2 expression using the Real-Time PCR assay, since it is the 
mature miRNA sequence primes the assay. As these highly correlated miRNAs are located on 
chromosome 3, we have also examined this region. Analysis of this chromosome was performed 
as described for chromosome 13, using the segmentation algorithm to determine the ampli-
fied and deleted regions (miRNA-15b and miRNA-16-2 location 161.605.070 bp – 161.605.307 
bp). Deletion of this region on chromosome 3 was found in 2 MM patients samples. In contrast, 
amplification was found in 6 MM patient samples (Table 2 and S2).  
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NM_173605: KCNRG
Description Amplication Amplication with LOH Copy-Neutral LOH Deletion Deletion with LOH
Description Amplication Amplication with LOH Copy-Neutral LOH Deletion Deletion with LOH
p13 p12 p11.2 p11.1 q11 q12.11 q12.3 q13.3 q14.11 q14.2 q14.3 q21.1 q21.2 q21.31 q21.32 q21.33 q31.1 q31.2 q31.3 q32.1 q32.3 q33.1 q33.3 q34
MM 26
MM 10
MM 6
MM 4
MM 1
MM 21
MM 8
MM 14
MM 7
MM 16
MM 15
MM 9
MM 13
MM 2
MM 23
MM 5
MM 24
MM 25
MM 3
MM 17
MM 26
MM 10
MM 6
MM 4
MM 1
MM 21
MM 8
MM 14
MM 7
MM 16
MM 15
MM 9
MM 13
MM 2
MM 23
MM 5
MM 24
MM 25
MM 3
MM 17
2)
3)
4)
1)B
A
q14.3
5’3’
3’
5’
NM_213590: TRIM13
NM_005798: TRIM13
NM_001007278: TRIM13
NM_052811: TRIM13
NM_199464: KCNRG
NM_020456: C13orf1
NM_001127482: C13orf1
NT_024524.13: miRNA-15a/miRNA-16-1
Figure 1. Copy number alterations of chromosome 13 as determined by paired segmentation analysis. SNP 
mapping arrays (Illumina Infinium HumanHap550 Genotyping BeadChip) were used to determine the exact 
deleted regions at chromosome 13 MM cases. (A) The results of the paired segmentation analysis of chromo-
some 13 (20/26 MM patients). (B) A region on chromosome 13; 13q14.3, including the miRNA-15a and miRNA-
16-1 locus, is depicted at larger magnification. In panel 1; the miRNA-15a and miRNA-16-1 locus (star) is shown 
within the genome browser. Panel 2 shows the results of the paired segmentation analysis in more detail. 
A deletion (orange and purple) was detected in 15/20 MM patients. Uniparental disomy (UPD; green) was 
detected in patient MM 17, in the regions flanking miRNA-15a and miRNA-16-1. CN values for SNPs (red dots) 
are plotted in panel 3. CN values of 2 represent diploid copy number, whereas values of 1 and 0 represent 
heterozygous and homozygous deletion respectively. A representative patient (MM 7) shows values of 1 or ≤ 
1, indicating deletion. In panel 4; the B allele frequency is displayed. Each point (green dot) represents the B 
allele frequency of one SNP. B allele frequencies of 0 and 1 represent homozygous signals (AA or BB), while an 
allele frequency of ~0.5 represents an equal contribution from both alleles (AB). A representative MM patient 
sample (MM 7) shows a deletion with LOH (black box in segmentation panel) which produces a characteristic 
pattern that lacks heterozygote signal.
For visualization purposes the order of the samples is MM 26, MM 10, MM 4, MM 1, MM 21, MM 8, MM 14, MM 
7, MM 16, MM 15, MM 9, MM 13, MM 2, MM 23, MM 5, MM 24, MM 25, MM 3, MM 17.
An overview of the results of FISH and CNV analysis for chromosome 13 and 3 is shown in 
Table 1 and 2, respectively. The combined analysis of FISH and CNV revealed 20 (76.9%) of 26 MM 
patients with a chromosome 13 aberration at 13q14.3.
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MiRNA-15a and miRNA-16 gene expression in MM patients
A TaqMan miRNA assay was used to determine the relative miRNA-15a and miRNA-16 expres-
sion levels in myeloma cells of 26 MM patients. Both miRNA-15a and miRNA-16 were expressed 
in all 26 MM samples, although the level of expression varied across the samples. The median 
expression value of miRNA-15a and miRNA-16 was 0.84 and 1.16, respectively (both values in 
log2 scale, relative to the geometric mean). Figure 2 shows that no significant association was 
found between the chromosome 13 deletion status and the miRNA-15a expression levels using 
FISH (P = 0.38) and CNV (P = 0.25). In addition, statistical analysis showed no significant associa-
tion between miRNA-16 expression and chromosome 13 status determined by FISH (P = 0.40) 
and CNV (P = 0.27). Since we are not able to separate miRNA-16-1 and miRNA-16-2 expression, 
results are only shown for miRNA-15a. We also evaluated the expression levels of miRNA-15a 
and miRNA-16 in CD138 sorted plasma cells from normal individuals. MiRNA-16 was found to be 
expressed at 1.4 fold lower levels in normal plasma cells when compared with myeloma plasma 
cells, suggesting an increased expression of this miRNA in MM.
These findings demonstrate that miRNA-15a and miRNA-16 are displayed at a range of expres-
sion levels in MM patients which are higher than in normal plasma cell counterparts. The expres-
sion of these miRNAs varies independent of the chromosome 13 status.
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Figure 2. Copy number of chromosome 13 in correlation with miRNA-15a gene expression in multiple 
myeloma (MM) patient samples. A TaqMan miRNA assay was used to determine the relative miRNA-15a expres-
sion levels in myeloma plasma cells of 26 MM patients. The normalized relative expression of miRNA-15a in 
26 MM patient samples is displayed on the X-axis. MiRNA-15a is expressed in all 26 MM samples, although 
the level of expression varies across the samples. SNP mapping arrays (Illumina Infinium HumanHap550 
Genotyping BeadChip) were used to determine copy number values of chromosome 13, which are shown 
on the Y-axis. Copy number values of 2 were detected in 6/26 MM patients, indicating diploid copy num-
ber; values less than 2 represent heterozygous and homozygous deletions, which were found in 20/26 MM 
patients. Patients are colored by chromosome 13 status as determined by FISH; being either normal (dark 
grey) or deletion (light grey). Segmentation analysis has shown 8 additional patients with a chromosome 13 
aberration in the region containing miRNA-15a and miRNA-16-1. A linear regression line reveals there is no 
correlation between the miRNA-15a expression and the chromosome 13 status as determined by segmenta-
tion analysis. 
The picture insert shows a box plot representation of the normalized relative expression of miRNA-15a in 26 
MM patients samples (X-axis), in correlation with the chromosome 13 status determined by segmentation 
(Y-axis). The box plot shows no significant difference in miRNA-15a gene expression (P = 0.38 and P = 0.25 
respectively, Mann-Whitney U test) between patients with a deletion (light grey, n= 6) and normal chromo-
some 13 status (dark grey, n=20). 
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Discussion
In recent years, the prognostic and biological significance of chromosome 13 deletions has been 
extensively studied in MM. Deletion of chromosome 13 is detected in approximately 50% of 
patients by FISH and in 10–20% of patients using conventional karyotyping.11,23-25 It has been 
suggested that patients with a whole chromosome 13 deletion detected by cytogenetics, have 
a worse prognosis in contrast to chromosome 13q deletions detected by FISH.26-29 Nevertheless, 
the presence of 13q deletions and their impact on prognosis suggest that one or more tumor 
suppressor genes are located on chromosome 13q and may be involved in the pathogenesis 
of MM. The identification of a tumor suppressor gene remains a difficult task, and currently, no 
other genes flanking the miRNA-15a and miRNA-16-1 region appear to have a role in pathogen-
esis of MM. Calin et al.,16 reported that in CLL patients; miRNA-15a and miRNA-16-1; located on 
chromosome 13q14, are often downregulated or deleted and therefore could play a role in the 
pathogenesis of CLL. Loss of chromosome 13 occurs, like in MM, in approximately 50% of CLL 
patients.30 However, there are essential differences between MM and CLL concerning chromo-
some 13q deletions. First of all, chromosome 13q deletions have an adverse prognostic role in 
MM, whereas CLL patients with 13q deletions as a sole abnormality have the longest estimated 
survival times.30 Thus, the role of miRNA-15a and miRNA-16-1 in the mechanism behind the 
prognostic significance of chromosome 13q deletions in CLL and MM may differ. Furthermore, 
homozygous deletions seem to be rare in MM but are observed in approximately 10% of CLL 
patients. This was demonstrated in the present study, whereby all patients presenting with a 
deletion were heterozygous. Finally, deletions of chromosome 13 in CLL patients are of vary-
ing length, but almost always involve the 13q14.3 region, whereas in MM, the deletions often 
involve loss of the entire chromosome.31
Downregulation of miRNA-15a and miRNA-16-1 has been reported in cases of MM, CLL and 
diffuse B Cell Lymphomas.16-17,32 In this study, the two miRNAs were expressed in all 26 MM 
patients examined, even when chromosome 13 was deleted. Since these two miRNAs may play 
a role in the pathogenesis of MM, other regulatory mechanisms must exist.15,17  One could argue 
that the two miRNA genes are still present due to a partial deletion. Applying the segmentation 
algorithm, we could accurately determine the region of deletion according to the presence of a 
nearby SNP and to detect regions of allelic imbalance due to copy number loss or gain, or copy 
neutral LOH.33-34 The segmentation method can be applied to both paired and unpaired tumor 
samples, showing an increased sensitivity and high specificity for detecting allelic imbalances in 
heterogeneous samples.33-34 The CNV analysis demonstrated that the region where miRNA-15a 
and miRNA-16-1 are located was deleted in 20 MM patient samples. It is therefore highly un-
likely that chromosome 13 deletions that are not detected by CNV analysis are partial deletions. 
Compensation by the non-deleted allele could explain the expression level of miRNA-16 since all 
chromosome 13 deletions in this study are heterozygous.
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In addition, a highly correlated cluster of miRNAs, miRNA-15b and miRNA-16-2, are located on 
chromosome 3. The observed miRNA-15a and miRNA-16 expression levels could be due to persis-
tent expression of these miRNAs. With the Real-Time PCR assay used in this study, we are not able 
to make a distinction between miRNA-16-1 and miRNA-16-2 expression, since the mature miRNA 
sequence is identical for both.
Currently, FISH analysis is the standard method to determine chromosome 13 deletion status. 
Large genomic aberrations can be detected by FISH; nevertheless, the resolution of this method 
is limited. As this study shows, FISH might provide false-negative outcomes. SNP mapping arrays 
increase the resolution enormously and provide a more robust and sensitive determination of 
chromosomal aberrations than FISH as we have shown. Indeed, 8 additional patients were found 
to have a chromosome 13 deletion at the miRNA-15a and miRNA-16-1 location not detected by 
FISH. CNV analysis using SNP mapping arrays seems to be a highly specific method to determine 
chromosomal regions of deletion or amplification status. In addition, the high resolution of SNP 
mapping arrays may facilitate the identification of tumor suppressor genes and oncogenes in-
volved in the pathology of MM. Although this study clearly shows the discrepancy between FISH 
and CNV analysis and the efficacy of SNP mapping arrays in detecting chromosomal aberration, 
there are some issues regarding the accuracy of the method that have to be taken into account. 
First, substantial CNV has been reported in germline DNA. For that reason it is most desirable to 
use matched tumor and control samples for paired analysis. It is important, especially for smaller 
aberrations, that a direct comparison between tumor DNA and matched germline DNA is per-
formed.35 Because paired CN analysis was carried out for 20/26 MM samples, this makes the data 
highly reliable. Furthermore, CNV calculations are based on the allele intensity data. The quality 
of the allele intensity, which is indirectly measured by SNP call rate, should be sufficient and SNP 
arrays with low call rates should therefore be removed from the analysis.   
BCL2, an anti-apoptotic gene, is often expressed in many types of cancer, including leukemia’s 
and lymphomas which imply a role for BCL2 in the pathogenesis of these malignancies.36 A 
recent study  suggests that both miRNA-15a and miRNA-16-a negatively regulate BCL2-mRNA 
levels in CLL.37 Downregulation or deletion of miRNA-15a and miRNA-16-1 may therefore result in 
increased expression of BCL2 and inhibition of apoptosis. In MM we did not observe a correlation 
between the miRNA-15a and miRNA-16 expression levels and the BCL2 protein and gene expres-
sion (data not shown). 
In conclusion, the current study has shown that CD138 MACS plasma cells of MM patients 
express both miRNA-15a and miRNA-16 heterogeneously. The levels of miRNA-15a and miRNA-16 
expression vary independent from the presence of chromosome 13q deletions. In addition, these 
high resolution, genome-wide SNP mapping arrays may provide an excellent tool to identify 
partial chromosomal aberrations and genes.
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Single nucleotide polymorphism association studies in multiple myeloma
Although much progress has been made in the treatment of multiple myeloma (MM) during 
the last decade, many patients die from treatment failure. In addition, a large number of MM 
patients experience serious adverse events from the drugs they receive. There is a critical need 
to discover new drugs, and in addition, it is important to optimize existing drug regimens to 
minimize adverse events and to optimize drug efficacy. 
There are several reasons why a patient may experience excessive toxic side effects includ-
ing dosing errors, drug–drug interactions, drug allergies and medication errors. However, in 
the majority of patients with severe adverse drug reactions no explanation can be found. Since 
the completion of the Human Genome Project1 and the International HapMap Project,2 there 
has been increasing interest in the patient’s individual genetic disposition as a risk factor for 
the development of adverse drug events, and as a potential variable for drug efficacy. After the 
discovery of the first single nucleotide polymorphism (SNP), it became clear that SNPs could 
have an impact on individual drug response. The human genome is estimated to have about 
12 million common SNPs. Their potential to contribute to inter-individual differences in drug 
responsiveness, or the frequency of toxic side effects is well recognized. An important aim of 
SNP association studies is to identify SNPs that contribute to the activity, toxicity or kinetics of a 
particular drug, and the variability across a patient population; the field of pharmacogenetics.3 In 
pharmacogenetics, the aim is to assess a patient’s individual genetic variability in relation to drug 
effects. A pending question of clinical importance in cancer is whether pharmacogenetics can 
be used to predict adverse events and the clinical outcome following treatment, which would 
lead to the development of genetic tests for the identification of the most suitable drug for a 
specific patient. So far, the translation of pharmacogenetic research into clinical practice has not 
yet been made. Ultimately, the utility and clinical application of pharmacogenetics to improve 
safety, drug efficacy and quality of life of the patient must be supported by prospective analyses 
in comprehensive clinical trials. 
The main focus of part I was to study the pharmacogenetics in patients with multiple myeloma; 
a fatal bone marrow cancer. We studied the inherited genetic variations in newly diagnosed 
MM patients, with the aim of identifying genetic variability that may predict treatment effects. 
Patients who were included in 3 large prospective clinical trials were genetically characterized, 
and their pharmacogenetics was compared with the clinical data. We took a hypothesis-driven 
candidate gene approach because the number of events to be analyzed would be small, and we 
were aiming to identify pertinent functional loci variants with moderate to large effect size. High 
quality genotype data with stringent quality controls of a homogenous population of similarly 
treated patients were studied, in order to minimize experimental artifact that can be found in 
many association studies.3 
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A pending question of clinical importance is whether genetic factors influence the susceptibil-
ity to development of MM. Until now, studies using genetic epidemiological methods have 
lacked power, due to the limited number of SNPs and samples. The study presented in chapter 
2 is the largest genetic epidemiology study that addresses this question in MM to date, and its 
design lays somewhere between a classical candidate gene study and a whole genome scan. 
We identified a number of SNPs showing causative effect with risk of developing MM. Classic 
epidemiological association studies have identified chronic immune stimulation; mediated via 
a number of environmental factors, as being a relevant association with the risk of developing 
MM.4 Herein, we described associations with genetic variation within genes mediating the 
biology of B lymphocytes that could mediate such immune effects, and within which minimal 
biological variation could affect the risk of transformation to myeloma. We saw association with 
2 SNPs in FCLR5 and SELP, derived from chromosome 1; a region which is frequently associ-
ated with MM progression and poor clinical outcome.5-7 In addition, we found associations in 
genes involved in micro environmental interactions and B cell signaling pathways, which are 
relevant to the development of MM; possibly by mediating cell survival following genetic dam-
age. The potential role of environmental exposures in MM risk has been previously suggested, 
but replication has proven difficult. In this context, we identified associations with absorption, 
distribution, metabolism, excretion (ADME) genes including CYP19A1 and CYP1A2, opening the 
way for further validation in studies designed to investigate gene environment interactions. 
Finally, we have shown an association with genetic variation in genes involved in growth factor 
signaling pathways as suggested previously, the most investigated being IL-6, IL-1B, TNFα, and 
NFκB. Although the associations seen are strong, and are informative about both the biological 
and environmental contributions to MM risk, this hypothesis-driven approach cannot detect as-
sociations outside the candidate panel, and will not observe associations potentially detectable 
by a genome-wide approach. 
Another application of pharmacogenetics is the identification of inherited genetic variations 
that play a role in the development of adverse events following treatment. In chapter 3, we 
studied the association of SNPs with thalidomide induced venous thromboembolism (VTE). 
Patients with MM have an increased risk (5-10%) to develop VTE because of the underlying dis-
ease, concomitant thrombophilic factors, and the administration of chemotherapy.8 In patients 
treated with thalidomide alone, or in combination with other agents such as anthracyclins and 
dexamethasone,9-10 VTE rates increase to 10-15%.11-13 In contrast, is has been reported that VTE 
rates decrease following bortezomib treatment.14-18 Guidelines have recently been established to 
govern clinical indicators for intervention, but these prognostic factors can be difficult to identify 
and use clinically.19 Given that genetic tests to identify patients at risk are not clinically avail-
able yet, it is of great importance that the management of adverse events is optimal. To come 
to a decision about which prophylaxis strategy is most suitable, causative factors need to be 
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identified. Thus, the application of pharmacogenetics for the identification of the mechanisms 
underlying the development of adverse events is of great importance. The main challenge in 
this is to understand the biological context in which these genetic variants act, and how they 
determine an adverse event such as VTE. The results of chapter 3 contributed considerably to 
reaching this aim. Interestingly, despite a comprehensive analysis of the genetic variation within 
the coagulation and prothrombotic pathway, we could not find evidence for a significant asso-
ciation of genetic variation within these pathways with VTE risk following thalidomide exposure, 
suggesting other pathways to be involved in the development of VTE. Indeed, the set of 18 SNPs 
associated with thalidomide induced VTE could be divided into three groups; a response to DNA 
damage group including CHEK1, XRCC5, LIG1, ERCC6, DCLRRE1B, and PARP1; a cytokine response 
group containing NFKB1, TNFRSF17, IL-12B, and LEP; and a third related group of apoptosis with 
CASP3, PPARD, and NFKB1. These enrichment groups indicate that genetic variation in response 
to DNA damage and cytokine-mediated apoptosis modulates risk of developing a thalidomide 
related thrombosis. Variation in DNA repair capacity could readily affect the response of the 
myeloma clone to treatment, due to the direct relationship between the extent of DNA damage 
accumulation and the clinical response to alkylating agents.20 A rapid response and dissolu-
tion of myeloma clones with an impaired double stranded DNA repair pathway, would release 
greater pro-thrombotic factors that could be either micro-particles with surface tissue factor 
or cytokines and tissue factor. The greater thrombogenesis due to increased dissolution of the 
myeloma clone, may act additively with a dexamethasone-thalidomide interaction on plasma 
cells,21 giving rise to an increased number of VTEs.22-23 An alternative mechanism to explain the 
increased risk of a VTE associated with DNA repair genes, could be based on the observation 
that thalidomide can protect endothelial cells from doxorubicin induced apoptosis by restoring 
PAR-1 expression;24 promoting sub-endothelial tissues factor exposure, endothelial dysfunction, 
platelet activation and consequently increase the thrombosis risk.24-26 Under these conditions, 
decreased DNA repair capacity could promote clot formation at the endothelium.
As part of the analysis in chapter 3, recursive partitioning was used to identify a limited number 
of SNPs that, when analyzed together, can predict the risk of VTE. A set of 7 SNPs was identified 
that could correctly predict VTEs in 70% of the patients. Testing for these SNPs has the potential 
for being clinically useful for identifying high risk patients for whom therapeutic intervention 
is required. The intervention strategies for patients may change according to the genetically 
defined risk. 
Among the variety of adverse events that are associated with MM treatment, peripheral neu-
ropathy (PN) has been one of the principal non-hematological, dose-limiting adverse events of 
thalidomide and bortezomib treatment. In chapters 4, 5, and 6, we addressed questions related 
to PN in newly diagnosed MM patients who were treated with thalidomide or bortezomib. PN, 
induced by thalidomide (TiPN) or bortezomib (BiPN), is one of the most frequent and potentially 
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disabling adverse events,27-28 frequently requiring dose modification or discontinuation which 
negatively affects clinical endpoints and quality of life.29 Baseline myeloma associated PN is 
observed in up to 54% of newly diagnosed MM patients.30-32 Grade 1-2 BiPN can occur in up to 
27-75% and 25-33% of patients with recurrent or newly diagnosed MM, respectively, while grade 
3-4 BiPN may affect 0-30% of patients with recurrent disease and 0-18% with newly diagnosed 
myeloma.17 The overall TiPN incidence ranges from 12-44%, or grade 1-2 of 22%, and grade 3-4 
of 6%.33 
Chapter 4 provides new insights into the mechanisms underlying TiPN. Our results were consis-
tent with the hypothesis that an individual’s risk of developing TiPN can be mediated by SNPs 
in genes governing repair mechanisms, and inflammation in the peripheral nervous system. In 
addition, a number of ATP-Binding Cassette (ABC) transporters genes were linked with TiPN in-
cluding: ABCC1, ABCC2, ABCA1, and ABCB1. Interestingly, thalidomide can modulate the function 
of ABCC2 and ABCB1,34 both of which are active in neuronal function. Pathway analysis of the 
TiPN associated SNPs, highlights the association with genes involved in the development of the 
central and peripheral nervous system. A SNP found within a conserved promoter region, affect-
ing the expression of the gene SPRR1A, was significantly associated with TiPN. The gene SPRR1A 
is expressed by axotomized neurons and promotes axonal outgrowth.35 Variation in neurological 
genes may dictate the ability of a damaged neuron to undergo repair, and may mediate risk of 
neuropathy. 
We have shown that simple clinical factors do not allow the identification of patients at greater 
risk of neuropathy following thalidomide exposure, for which dose adjustment, or cessation of 
therapy would be appropriate. Consequently, we have attempted to define a limited number 
of SNPs that can identify high risk patients suitable for more intensive clinical monitoring. In 
this approach, we have used two different risk classification methods: the risk score method 
and recursive partitioning, both of which can identify patients at increased risk, although the 
predictive value of these methods is not adequate to totally avoid thalidomide usage. However, 
this approach can be used to identify patients requiring greater clinical vigilance and suitable 
counseling. The poor risk prediction in our classifiers is due to a number of limitations, which 
include: a) naive assumptions in modeling methods; the risk score method assumes interac-
tions to be solely additive, whilst recursive partitioning method interactions are assumed to be 
uni-directional, b) hypothesis-driven approaches do not consider all variation contributing to 
an outcome, c) population specific effects, and d) the impact of rare variation. Despite these 
drawbacks, the limited number of SNPs identified in this study can be used as a simple and useful 
method for identifying patients at high risk of TiPN, who in turn may benefit from greater clinical 
vigilance.
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In chapters 5 and 6, SNP association studies were performed to gain more insight into the 
mechanisms involved in the development of BiPN. In the future, it will become increasingly 
important to combine and integrate different microarray technologies in order to come to a 
detailed understanding of a disease. Conclusions that have clinical consequences will need to 
be based on the results of different platforms. The integration of gene expression and genomic 
data, could lead to a better understanding of the variation in genomic structure that has an effect 
on gene regulation, and how this contributes to disease. In chapter 6, we performed an integra-
tive analysis by combining gene expression and SNP data of newly diagnosed MM patients, who 
did or did not develop BiPN or vincristine induced PN (ViPN). 
The results discussed in chapters 5 and 6 indicate that the mechanisms underlying the devel-
opment of BiPN are multifactorial, with different molecular pathways being implicated in early 
onset (after 1 cycle of bortezomib induction treatment) and late onset (after 2 or 3 cycles of 
bortezomib induction treatment) BiPN. Our findings strongly suggest an interaction between 
myeloma related factors, and the patient’s genetic background in the development of BiPN. A 
pathway of major relevance involved in the development of late onset BiPN, is the inflammatory 
pathway. SNPs that lie within proinflammatory cytokines such as TNFα, PARP1, and MBL2 are as-
sociated with late onset BiPN. Particularly interesting is the association with TNFα, since TNFα has 
been implicated in several neurodegenerative diseases, including multiple sclerosis, Alzheimer 
disease, human immunodeficiency virus-related encephalopathy, and diabetic neuropathy.36-40 
Bortezomib’s target; NFκB, is intricately related to the TNF receptor system in the nervous 
system, and interacts with PARP1, which is involved in neuronal cell death.41 While there is no ef-
fective treatment available for BiPN apart from dose modification or treatment discontinuation, 
the recognition of the inflammation system being involved in the pathogenesis of BiPN, may 
provide new therapeutic targets to be explored. Promising results have been reported for TNFα 
suppression using infliximab in diabetic polyneuropathy in animal models,42-44 which supports 
the possible application of TNFα inhibitors or monoclonal antibodies for the treatment of BiPN. 
This aspect will clearly need to be studied further.
Our results also suggest a possible direct involvement of neuropathy susceptibility genes and 
genes that regulate neuronal proliferation, and damage repair in late onset BiPN. We noted up-
regulation of the superoxide dismutase gene SOD2 in myeloma plasma cells; SOD2 is regulated 
by TNFα and NFκB, and is known to have a role in the survival of neurons. Patients with diabetes 
and a polymorphism in the SOD2 gene, leading to reduced SOD2 activity, have been shown to be 
at increased risk of developing diabetic peripheral neuropathy.45 The protective effect of SOD2 
might be eliminated with bortezomib induced apoptosis, which may trigger a susceptibility to 
oxidative stress in treated patients. While the involvement of these genes may be expected, we 
are the first to describe the involvement of the inflammation system in the pathogenesis of BiPN, 
which may provide new therapeutic targets to be explored. 
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Finally, the genetic profiles of patients with early onset BiPN suggest the involvement of 
genes involved in AMPK-mediated signaling. The possible role of AMPK-mediated signaling is 
of particular interest, because this enzyme functions by stimulating the signaling pathways that 
replenish cellular ATP supplies in response to low glucose, hypoxia, ischemia, or heat shock, 
which might be triggered in myeloma cells in response to bortezomib. Other genes associated 
with early onset BiPN are involved in apoptosis (RHOBTB2 and RASGRP1) and transcription. 
A comparison of the molecular DNA profiles of TiPN and ViPN in chapter 4, and BiPN and ViPN 
in chapter 6, showed no overlap in associated genes or SNPs. Genes involved in cell cycle and 
proliferation were mainly associated with early onset ViPN, both in the analyses of genetic 
pathways and SNPs. An interesting observation is the involvement of inflammatory genes in all 
three types. Involvement of proinflammatory genes in early onset ViPN, was substantiated by the 
finding of SNPs in PARP1, LTA, and GLI1. Despite this overlap, we propose that the involvement of 
distinct molecular pathways is indicative of a fundamentally different pathological mechanism 
between these three types of neuropathy. In contrast, similar TiPN associated genes have been 
seen in studies investigating peripheral neuropathy in response to paclitaxel, and docetaxel, 
which result in sensory peripheral neuropathies, as opposed to the sensorimotor neuropathy 
associated with exposure to the vinca alkaloids and taxol.
Substantial challenges still remain before these discoveries find widespread application in clini-
cal practice. First, it is necessary to replicate the results in order to minimize the number of false 
positive and false negative classifications.46-48 The strongest evidence that a true genetic variant 
is associated with adverse events, and thus may be causal, is to replicate the result in a separate 
independent cohort.49 Additionally, one of the shortcomings of genetic association studies is 
that the identified association between a single genetic variant and a disease outcome may 
have been caused by linkage disequilibrium with another genetic variant. In using a candidate 
gene approach, it is therefore important to consider gene haplotypes. It is presumed that the 
identification of a few alleles within a haplotype block, can unambiguously identify all other 
polymorphic sites in its region. Furthermore, large sample sizes are needed to provide enough 
statistical power in order to detect the effect of a genetic variant on disease etiology, clinical 
outcome, or treatment side effects.
The candidate gene studies discussed in part I of this thesis, focused on the identification of SNPs 
that are most important for treatment related toxicity. Our results show that a candidate gene 
approach is successful for investigating drug toxicity. Our candidate gene studies have provided 
initial insights into genetic factors affecting susceptibility to the adverse events VTE and PN. Our 
results indicate that the possibility to develop simple genetic tests (based on associated SNPs) to 
determine the most suitable drug for an individual MM patient may become possible in the near 
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future. The knowledge presented within this thesis, may therefore contribute to the develop-
ment of more personalized approaches of MM management. 
Undoubtedly, future research using either a candidate gene or a genome-wide approach, will 
contribute to further insights in the role of SNPs in MM. Integration of the different genomic 
techniques, including gene expression, miRNA expression and genome-wide SNP genotyping 
arrays, will lead to a more detailed understanding of MM, and the adverse events following treat-
ment. 
MicroRNA expression in multiple myeloma
MicroRNAs (miRNAs) have been shown to have an important role in various cellular processes, 
such as apoptosis, differentiation and development. There is considerable potential to target 
miRNAs as a novel approach in the treatment of MM. It is therefore of great importance to eluci-
date the miRNA expression pattern in MM and determine the role of miRNAs in MM pathogenesis. 
Although we are at an early stage of understanding the roles of miRNAs in MM, the importance 
of these molecules is clear. It has been previously shown that gene expression profiling can be 
used for the classification of MM.50-52 In addition to this, it has become clear that the possibility 
exists to differentiate between normal plasma cells and myeloma plasma cells based on unique 
miRNA expression signatures.53-55 In chapter 8, we performed a miRNA expression profiling study 
which confirms this finding. This study demonstrated that the expression of various miRNAs in 
MM is deregulated compared to normal plasma cells. Unsupervised analysis showed that MM 
patients can be classified according to their miRNA expression pattern and that these miRNA 
profiles were not characterized by cytogenetic subgroups, as previously demonstrated with 
gene expression. Our results suggest that miRNA profiling could make an important contribu-
tion to the classification of MM. 
To understand the role of miRNAs in the pathogenesis of MM, it is necessary to determine 
the targets of significant miRNAs. It is well known that the identification of miRNA targets is dif-
ficult, due to the capability of miRNAs to bind their targets with imperfect complimentarity.56 To 
date, only a small number of specific targets have been experimentally validated. It is therefore 
interesting to see that an inverse correlation between miRNA-21 expression levels and two of its 
validated target genes; PDCD4 and RECK, could be identified. Analysis of the mRNA and miRNA 
levels as described in chapter 8 may identify miRNA-target interactions that result in mRNA 
degradation, and could lead to the identification of disease related miRNA targets.57-58
In other malignancies, a correlation has been shown between certain miRNAs and clinical 
outcome, which indicates the potential of miRNAs to be used in determining a specific course of 
treatment.59-60 Indeed, in chapter 8 we identified a borderline significant association between the 
expression of three miRNAs and overall survival. Further studies in the near future, must confirm 
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and validate our findings and thereby the conclusions regarding the ability of these miRNAs to 
predict clinical outcome in MM. 
A large number of miRNAs are located at fragile sites across the human genome. These sites 
are often deleted or amplified at a common breakpoint, and they are frequently associated 
with cancer.61 Therefore, miRNAs have been suggested to function as tumor suppressor and 
oncogenes, and play a role in the pathogenesis of MM.55 In chronic lymphocytic leukemia (CLL), 
miRNA-15a and miRNA-16-1; located on chromosome 13q14, are frequently downregulated or 
deleted, and therefore a tumor suppressor activity and pathogenic role has been suggested.62-63 
A similar function has been hypothesized for miRNA-15a and miRNA-16-1 in MM. The results of 
chapter 9 suggest otherwise, and provided new insights into the prognostic implications of 
chromosome 13q deletions. We investigated the expression of miRNA-15a and miRNA-16 in MM, 
and studied the potential association between miRNA expression levels and chromosome 13q 
deletions in myeloma plasma cells. We demonstrated that the levels of miRNA-15a and miRNA-16 
expression vary, independent from the presence of chromosome 13q deletions. Since chromo-
some 13q deletions have an impact on prognosis,64-67 it will be important to assess whether our 
findings can be reproduced in independent data series. 
The results presented in part II of this thesis may contribute to a better understanding of the 
complex role of miRNAs in the pathogenesis of MM. It has become clear that the identification 
of altered miRNA expression, as well as their targets, may provide new opportunities for thera-
peutic strategies.
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Summary
Although considerable progress has been made during the past decade in the treatment of 
multiple myeloma (MM), many patients die from treatment failure. In addition, a large number 
of MM patients experience serious adverse side effects to the drugs they receive. Although 
the introduction of drugs such as thalidomide and bortezomib have enhanced the ability to 
move toward personalized treatment, there still remains a critical need for novel treatment ap-
proaches. In addition, it is important to optimize existing drug efficacy and drug regimens in 
order to minimize adverse events. 
Chapter 1 presents a general introduction to multiple myeloma with emphasis on single nucleo-
tide polymorphisms (SNPs), and microRNAs (miRNAs). In addition, an outline of the subsequent 
chapters is provided.
Following the first chapter, the thesis is separated into two parts: Part I and Part II. 
Part I on SNP association studies in MM comprises chapters 2, 3, 4, 5, and 6.
Pharmacogenetics; the field that studies the role of a patient’s individual genetic variability on 
the activity, toxicity or kinetics of a particular drug, will allow the adaption of a treatment to the 
genetic profile of a patient. Variation in the genetic profile of a patient is often due to SNPs, which 
can affect a patient’s response to drugs, and the development of toxic adverse events. Therefore, 
gaining better insight into the SNP profile of patients will eventually allow personalized treat-
ment and prediction of adverse events.
In chapter 2, a hypothesis-driven approach is taken to examine the role of inherited genetic 
variation within MM, using a custom genotyping array to study 2595 presenting MM cases of 
European origin; derived from the UK, US, and The Netherlands. The custom SNP Bank On A Cure 
(BOAC) array consists of 3404 SNPs in 964 genes, focusing on SNP variation in molecular path-
ways involved in the pathogenesis and treatment response of MM. In order to understand the 
distribution of these variants within the normal population, we access 8974 population control 
genotypes from publicly available datasets. A comparison of the genotypic distribution between 
the case and control populations allows us to identify genetic variation that associates with MM 
predisposition. These genetic variations include nonsynonymous SNPs in immunity genes FCRL5 
and SELP; both derived from chromosome 1, a region frequently associated with MM progression 
and poor clinical outcome. A nonsynonymous SNP in CAMKK2, mediating signaling via cytokine 
signaling pathways and critical for myeloma cell function is also associated with MM. The po-
tential role of environmental exposures in MM risk is supported by the association with a SNP in 
CYP2C19; an absorption, distribution, metabolism, excretion (ADME) gene.
Chapter 3 describes the influence of SNPs on the susceptibility to developing a venous throm-
boembolism (VTE). VTE, with the subsequent risk of pulmonary embolism, is a major concern in 
188 Chapter 10
the treatment of MM patients with thalidomide. Our analysis shows that a set of SNPs associating 
with thalidomide induced VTE is enriched in genes and pathways important in drug transport 
and metabolism, DNA repair, and cytokine balance. In addition, recursive partitioning analysis 
defines a set of SNPs that could be used to identify patients at high risk for VTE. 
In chapter 4, the association between SNPs and thalidomide induced peripheral neuropathy 
(TiPN) is assessed using the BOAC SNP array. Peripheral neuropathy (PN) is a serious adverse 
event in MM patients. Rates of TiPN vary from 15-70%, with the risk of neuropathy being related 
to the cumulative dose and duration of therapy. The repose to TiPN is dose reduction or with-
drawal of thalidomide, which can lead to symptom resolution in up to 16 weeks, however in 
some cases TiPN is irreversible. 
TiPN associations are identified with SNPs in ABCA1, ICAM1, PPARD, SERPINB2, and SLC12A6, and 
these results are cross validated in two independent prospective clinical trials. These findings are 
consistent with the hypothesis that an individual’s risk of developing TiPN can be mediated by 
SNPs in genes governing repair mechanisms and inflammation in the peripheral nervous system. 
It is also investigated whether TiPN SNP associations are related to exposure to thalidomide only 
or general drug related PN, and a second analysis is performed on patients treated with vincris-
tine. This identifies SNPs associated with vincristine induced peripheral neuropathy (ViPN), with 
a seemingly distinct underlying genetic mechanism. 
Peripheral neuropathy is also the dose-limiting toxicity of bortezomib treatment, which 
frequently requires dose reduction or treatment discontinuation. The mechanisms underlying 
bortezomib induced peripheral neuropathy (BiPN) are largely unknown. Therefore, in chapter 
5, a pharmacogenetic association study is performed in two prospective clinical trials using the 
BOAC SNP array. Stratified association analysis reveals a significant association between devel-
opment of BiPN and proinflammatory genes. The results strongly support the idea that SNPs 
located in important genes involved in inflammatory response such as TNFα, prothrombin, and 
PARP1, may play an important role in the pathogenesis of BiPN. A further unifying mechanism 
underlying BiPN is the inability to repair neurological damage. Another important finding in this 
study, is the association of SNPs with BiPN that lie within the essential neuropathy susceptibility 
genes IKBKAP, SERPINB2, and DPYD.
In chapter 6, the molecular factors associated with chemotherapy induced PN using gene 
expression profiles and SNP genotyping data are assessed. A comparison between ViPN and 
BiPN shows that different genetic factors are involved in the development of PN after vincristine 
or thalidomide treatment, suggesting a distinct molecular mechanism. Specifically, myeloma de-
rived genetic profiles and patient SNP data shows an association of genes involved in apoptosis 
and response to oxidative stress with early onset BiPN (after one treatment cycle). Inflammation 
and nervous system development dominate the genetic and SNP profile of late onset BiPN (de-
veloped later during induction treatment). Cell cycle and proliferation genes characterize early 
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onset ViPN, while inflammation factors and SNPs in ADME genes dominate the profile of late 
onset ViPN.
Part II on miRNA expression in MM comprises chapters 7 and 8.
Part II of this thesis focuses on the role of miRNA expression in the pathogenesis of MM. MiRNAs 
have been shown to have an important role in various cellular processes, such as apoptosis, 
differentiation and development. There is considerable potential to target miRNAs as a novel 
approach in the treatment of MM. It is therefore of great importance to elucidate the miRNA 
expression pattern in MM and determine the role of miRNAs in MM pathogenesis.
In chapter 7 we investigate miRNA expression profiles in myeloma plasma cells from 45 newly 
diagnosed MM patients. In the same series, gene expression profiles are determined in MM cells. 
This study demonstrates that miRNA expression in MM is deregulated compared to normal 
plasma cells. Unsupervised analysis shows that MM patients can be classified according to their 
miRNA expression pattern, and that these miRNA profiles are not characterized by cytogenetic 
subgroups. A trend towards better overall survival is observed for patients with high expression 
of let-7f, miRNA-194 and miRNA-296. Furthermore, integration of miRNA and mRNA data shows 
the putative interaction between miRNA-21 and two of its validated targets; PDCD4 and RECK, 
suggesting a functional relationship between miRNA expression and gene expression.
Chapter 8 assesses the question whether miRNA-15a and miRNA-16-1, located on chromo-
some 13q14, are downregulated or deleted in 26 MM patients. Deletion of chromosome 13, 
observed in more than 50% of MM patients, is associated with poor prognosis; however, a tumor 
suppressor gene has not yet been identified in the region. Chromosome 13q deletions are deter-
mined by copy number variation (CNV) using genome-wide SNP arrays and fluorescence in situ 
hybridization (FISH). CNV analysis reveals a number of additional patients with a chromosome 
13q deletion. This study shows that MM plasma cells express both miRNA-15a and miRNA-16 
heterogeneously. The levels of miRNA-15a and miRNA-16 expression vary independent of the 
presence of chromosome 13q deletions. 
Chapter 9 as final chapter represents a general discussion in which the described results of the 
pharmacogenetic studies are discussed in more depth and placed in a broader context.
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Samenvatting
Ondanks de aanzienlijke vooruitgang van de behandeling van multipel myeloom (MM) in het 
afgelopen decennium, sterft een groot deel van de patiënten door het falen van de behande- 
ling. Tevens is er een groot aantal MM patiënten met ernstige bijwerkingen van de medicijnen. 
Hoewel de introductie van nieuwe medicijnen zoals thalidomide en bortezomib hebben 
bijgedragen aan de weg naar een gepersonaliseerde behandeling, blijft het noodzakelijk om 
nieuwe behandelmethoden te ontwikkelen. Daarnaast is het van groot belang om bestaande 
behandelmethoden te optimaliseren ter voorkoming van ernstige bijwerkingen. 
Hoofdstuk 1 is een algemene introductie over multipel myeloom, waarin de nadruk ligt op single 
nucleotide polymorfismen (SNPs) en microRNAs (miRNAs). Ook wordt er een kort overzicht van 
de hierop volgende hoofdstukken gegeven.
Na hoofdstuk 1 bestaat dit proefschrift uit twee afzonderlijke delen: Deel I en Deel II.
Deel I beschrijft SNP associatie studies in MM en bestaat uit de hoofdstukken 2, 3, 4, 5 en 6.
Farmacogenetica; het veld dat de invloed van de individuele genetische variabiliteit op de 
activiteit, toxiciteit en kinetiek van een bepaald geneesmiddel onderzoekt, draagt bij aan de 
ontwikkeling van de aanpassing van een behandeling van een patiënt aan de hand van zijn of 
haar genetisch profiel. Variatie in het genetisch profiel van een patiënt is vaak te wijten aan SNPs, 
welke de respons op een geneesmiddel en de ontwikkeling van toxische bijwerkingen kunnen 
beïnvloeden. 
In hoofdstuk 2 wordt met behulp van een hypothese gestuurde aanpak de rol van erfelijke 
genetische variatie binnen MM bestudeerd, waarbij gebruik gemaakt wordt van een aangepaste 
genotyperings array om 2595 MM patiënten van Europese afkomst bij aanvang te onderzoeken; 
afkomstig uit de Verenigde Staten, Groot-Brittannië en Nederland. De aangepaste Bank On A 
Cure (BOAC) array bestaat uit 3404 SNPs in 964 genen, gericht op SNP variatie in moleculaire 
signaalroutes die betrokken zijn bij de pathogenese en de respons op de behandeling van MM. 
Met het doel de distributie van deze varianten binnen de normale populatie te begrijpen, 
hebben we toegang gehad tot 8974 controle genotypen uit publiek toegankelijke datasets. 
Door een vergelijking te maken tussen de distributie in patiënten en controle populaties is het 
mogelijk geweest polymorfismen te identificeren, die geassocieerd zijn met het risico op MM. 
Onder deze polymorfismen vallen nonsynonymous SNPs in de immuun genen FCRL5 en SELP; 
beide afkomstig van chromosoom 1, een regio die vaak geassocieerd is met MM progressie en 
een slecht klinisch resultaat. Een nonsynonymous SNP in CAMKK2, die de signalering via de cy-
tokine signaalroutes beïnvloedt en cruciaal is voor het functioneren van myeloomcellen, wordt 
ook geassocieerd bevonden met MM. De mogelijke rol van omgevingsfactoren in het risico op 
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MM wordt ondersteund door de associatie met een SNP in CYP2C19; een absorptie, distributie, 
metabolisme, en excretie (ADME) gen. 
Hoofdstuk 3 beschrijft de invloed van SNPs op de gevoeligheid voor het ontwikkelen van 
een veneuze trombo-embolie (VTE). VTE, met het daaruit voortvloeiende risico op een longem-
bolie, is een groot probleem bij de behandeling van MM patiënten met thalidomide. De analyse 
toont aan dat een set van SNPs, geassocieerd met thalidomide geïnduceerde VTE, verrijkt is 
met genen en signaalroutes die een belangrijke rol spelen in het transport en de distributie van 
geneesmiddelen, DNA herstel en cytokine evenwicht. Bovendien wordt met behulp van een 
recursieve partitionerings analyse een SNP set gedefinieerd, die gebruikt zou kunnen worden bij 
de identificatie van patiënten met een verhoogd risico op VTE. 
In hoofdstuk 4 wordt de associatie tussen SNPs en thalidomide geïnduceerde perifere neu-
ropathie (TiPN) nader onderzocht met behulp van de BOAC SNP array. Perifere neuropathie (PN) 
is een ernstige bijwerking bij MM patiënten. Percentages TiPN variëren van 15-70%, waarbij het 
risico op neuropathie gerelateerd is aan de cumulatieve dosis en de duur van de therapie. De 
behandeling van TiPN omvat een verlaging van de thalidomide dosis of het stopzetten van de 
behandeling, wat binnen 16 weken tot een afname van de symptomen kan leiden. In sommige 
gevallen is TiPN echter onomkeerbaar.
TiPN associaties worden geïdentificeerd met SNPs in ABCA1, ICAM1, PPARD, SERPINB2, en 
SLC12A6. Deze resultaten kunnen worden gevalideerd in twee onafhankelijke prospectieve 
klinische studies. De bevindingen zijn consistent met de hypothese dat het risico van een 
individu op het ontwikkelen van TiPN gestuurd kan worden door SNPs in genen belangrijk in 
herstel- en ontstekingsmechanismen in het perifere zenuwstelsel. Er wordt ook onderzocht of 
TiPN SNP associaties gerelateerd zijn aan de blootstelling aan thalidomide alleen of geneesmid-
delen gerelateerde TiPN in het algemeen, waarvoor een tweede analyse wordt uitgevoerd met 
vincristine behandelde patiënten. Hieruit komen SNPs naar voren die geassocieerd zijn met vin-
cristine geïnduceerde perifere neuropathie (ViPN), met een duidelijk verschillend onderliggend 
genetisch mechanisme.
Perifere neuropathie is eveneens een dosis-limiterende toxiciteit bij behandeling met 
bortezomib, waardoor het vaak nodig is de dosis te verlagen of de behandeling te staken. De 
mechanismen welke ten grondslag liggen aan bortezomib geïnduceerde perifere neuropathie 
(BiPN) zijn grotendeels onbekend. Met dit doel is er in hoofdstuk 5 een farmacogenetische as-
sociatie analyse uitgevoerd binnen twee prospectieve klinische studies met behulp van de BOAC 
SNP array. 
Gestratificeerde associatie analyse toont een significante associatie aan tussen de ontwikkel-
ing van BiPN en pre- inflammatoire genen. De resultaten ondersteunen sterk het idee dat SNPs, 
gelegen in belangrijke genen betrokken bij de inflammatoire respons, zoals TNFα, prothrombine 
en PARP1, mogelijk een essentiële rol spelen in de pathogenese van BiPN. Een ander onder-
liggend mechanisme is het onvermogen om neurologische schade te herstellen. Een belangrijk 
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resultaat van deze analyse is de associatie van BiPN met SNPs die in de essentiële neuropathie 
susceptibiliteitsgenen IKBKAP, SERPINB2 en DPYD liggen. 
In hoofdstuk 6 wordt onderzoek gedaan naar de moleculaire factoren die geassocieerd zijn 
met chemotherapie geïnduceerde PN, waarbij gebruik wordt gemaakt van genexpressie pro-
fielen en SNP genotypering data. Uit een vergelijking tussen ViPN en BiPN blijkt dat verschillende 
genetische factoren betrokken zijn bij de ontwikkeling van PN als gevolg van een behandeling 
met vincristine of thalidomide, waarmee gesuggereerd wordt dat de moleculaire mechanismen 
verschillend zijn. De myeloom afgeleide genetische profielen en SNP data van de patiënten laat 
met name een associatie zien tussen genen die betrokken zijn bij apoptose en de reactie op 
oxidatieve stress met de aanvang van BiPN in een vroeg stadium (na 1 behandelingscyclus). Ont-
stekings- en zenuwstelsel ontwikkeling domineren het genetisch- en SNP profiel van de in een 
laat stadium ontwikkelde BiPN (later tijdens de inductiebehandeling). Celcyclus en proliferatie 
genen zijn karakteristiek voor ViPN in een vroeg stadium, terwijl ontstekingsfactoren en SNPs in 
ADME genen het profiel van de in een laat stadium ontwikkelde ViPN domineren. 
Deel II beschrijft miRNA expressie in MM en omvat hoofdstuk 7 en 8.
Deel II van dit proefschrift richt zich op de rol van miRNA expressie in de pathogenese van MM. 
Het is inmiddels duidelijk geworden dat miRNAs een belangrijke rol spelen in verscheidene cel-
lulaire processen zoals apoptose, differentiatie en ontwikkeling. De nieuwe benadering in de 
behandeling van MM om miRNAs als target te gebruiken heeft aanzienlijk veel potentie. Het is 
daarom van groot belang om de miRNA expressieprofielen binnen MM te ontrafelen en de rol 
van miRNAs in de pathogenese van MM vast te stellen.
In hoofdstuk 7 is er onderzoek gedaan naar de miRNA expressieprofielen van myeloom 
plasmacellen van nieuw gediagnosticeerde MM patiënten. In dezelfde serie patiënten worden 
genexpressie profielen van MM cellen bepaald. In dit onderzoek komt naar voren dat miRNA 
expressie ontregeld is in vergelijking met normale plasmacellen. De analyse laat zien dat MM 
patiënten geclassificeerd kunnen worden op basis van het miRNA expressieprofiel, en dat deze 
miRNA profielen niet gekarakteriseerd worden door cytogenetische subgroepen. Patiënten met 
een hoge expressie van let-7f, miRNA-194, miRNA-296 neigen naar een betere algehele overleving. 
Daarnaast blijkt na het integreren van de miRNA en mRNA expressie data, dat er een mogelijke 
interactie tussen miRNA-21 en twee van zijn gevalideerde targets; PDCD4 en RECK bestaat, wat 
een functionele relatie tussen miRNA expressie en genexpressie suggereert. 
Hoofdstuk 8 onderzoekt de vraag of miRNA-15a en miRNA-16-1, gelegen op chromosoom 
13q14, een verlaagde expressie vertonen of gedeleteerd zijn in 26 MM patiënten. Deletie van 
chromosoom 13 komt in meer dan 50% van MM patiënten voor en is geassocieerd met een 
slechte prognose; een tumor suppressor gen is echter nog niet geïdentificeerd in deze regio. 
Chromosoom 13q deleties worden vastgesteld met behulp van copy nummer variatie (CNV), 
waarbij gebruik wordt gemaakt van genoom-wijde SNP array en fluorescent in situ hybridisatie 
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(FISH). CNV analyse doet een aantal extra patiënten met een chromosoom 13q deletie naar voren 
komen. Dit onderzoek laat zien dat MM plasma cellen zowel miRNA-15a als miRNA-16 heterogeen 
tot expressie brengen. De miRNA-15a en miRNA-16 expressie niveaus variëren onafhankelijk van 
de aanwezigheid van een chromosoom 13 deletie. 
Hoofdstuk 9 bevat tenslotte een algemene discussie waarin de beschreven resultaten van 
de farmacogenetische studies worden bediscussieerd en in een breder perspectief worden 
geplaatst.
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Abbreviations
ADME  Absorption, distribution, metabolism, excretion 
AML  Acute myeloid leukemia
ANOVA  Analysis of variances
AsCN  Allele specific copy number variation
BiPN  Bortezomib induced peripheral neuropathy
BM(SC)  Bone marrow (stromal cell)
BOAC  Bank On A Cure
bp  Base pair
cDNA  Complementary deoxyriboncleic acid
CI  Confidence interval
CLL  Chronic lymphocytic leukemia
CN(V)  Copy number (variation)
CR  Complete response
Ct  Threshold cycle
CTD  Cyclophosphamide, thalidomide, dexamethasone
CVAD  Cyclophosphamide, vincristine, adriamycin, dexamethasone
DNA  Deoxyribonucleic acid
DS  Durie-Salmon staging system
DVT  Deep vein thrombosis 
FDA  US Food and Drug Administration
FDR  False discovery rate
FISH  Fluorescence in situ hybridization
GM-CSF  Granulocyte macrophage-colony stimulating factor 
HapMap  Haplotype map
HDM  High-dose melphalan
HDT  High-dose therapy
HOVON  Stichting Hemato-Oncologie voor Volwassenen Nederland
HWE  Hardy-Weinberg Equilibrium
Ig  Immunoglobulin
IgH  Immunoglobulin heavy chain
IκB  Inhibitory kappa B
IL  Interleukin
IMiD  Immunomodulatory drug
ISS  International staging system
LD  Linkage disequilibrium
LOH  Loss of heterozygosity
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MAF  Minor allele frequency
MB  Megabases
MGUS  Monoclonal gammopathy of undetermined significance
MIP  Molecular inversion probe
miRNA  MicroRNA
MM  Multiple myeloma
mRNA  Messenger ribonucleic acid
NC  No change
NCI-CTC  National Cancer Institute-Common Toxicity Criteria
nCR  Near complete response
NFκB  Nuclear factor kappa B
NK cells  Natural killer cells
OR  Odds ratio
OS  Overall survival
PAD  Bortezomib, adriamycin, dexamethasone
PCR  Polymerase chain reaction
PE  Pulmonary embolism 
PFS  Progression free survival
PN  Peripheral neuropathy
PR  Partial response
RB1  Retinoblastoma-1
RNA  Ribonucleic acid
RT  Reverse transcription
RT-PCR  Reverse transcriptase polymerase chain reaction
SNP  Single nucleotide polymorphism
TAD  Thalidomide, adriamycin, dexamethasone
TiPN  Thalidomide induced peripheral neuropathy
TNFα  Tumor necrosis factor alpha
TrPN  Thalidomide related peripheral neuropathy
UPD  Uniparental disomy 
VAD  Vincristine, adriamycin, dexametasone
VGPR  Very good partial response
ViPN  Vincristine induced peripheral neuropathy
VTE  Venous thromboembolism
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